GO,Function,Proteins,Gene Name,Ontology group,Count of protein,Number of proteins detected within the genome,GO frequency within the dataset (%),GO frequency within the genome (%),P-Value,P-Values_BH
GO:0005576,extracellular region,P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q3SZV7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q0IIA4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q3MHN5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q2KJF1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q7SIH1(Evidence code:IEA/Database source:InterPro:IPR009048|I)O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)O46375(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q32PJ2(Evidence code:IEA/Database source:InterPro:IPR000074)P08037(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q8SPP7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P54228(Evidence code:IEA/Database source:InterPro:IPR001894|I)Q3ZCH5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P31096(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P02702(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P41361(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P02672(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q95122(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q2TBI0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P34955(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)A0JNP2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P81187(Evidence code:IEA/Database source:InterPro:IPR011360)P12799(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P22226(Evidence code:IEA/Database source:InterPro:IPR001894|I)P15467(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P02662(Evidence code:IEA/Database source:InterPro:IPR001588|I)P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q2UVX4(Evidence code:IEA/Database source:InterPro:IPR000020|I)Q3ZCL0(Evidence code:IEA/Database source:InterPro:IPR018244)P02754(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P02663(Evidence code:IEA/Database source:InterPro:IPR001588|I)Q2TBU0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P00735(Evidence code:IEA/Database source:InterPro:IPR000294|I)P79345(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P07688(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P30922(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q0VCM5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q29RU4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P26779(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P12763(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P28800(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q95121(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P02769(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P15497(Evidence code:IEA/Database source:InterPro:IPR000074)P24627(Evidence code:IEA/Database source:InterPro:IPR018195|I)Q29RQ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q2KIS7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q3T052(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P02666(Evidence code:IEA/Database source:InterPro:IPR001588)Q9MZ06(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P02676(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P00711(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P80457(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q0P569(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P62935(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q95114(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P80025(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P07589(Evidence code:IEA/Database source:InterPro:IPR000083)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P81265(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q3T0A3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q03247(Evidence code:IEA/Database source:InterPro:IPR000074)Q3SZR3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)Q28085(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964)P19660(Evidence code:IEA/Database source:InterPro:IPR001894|I)P01888(Evidence code:IEA/Database source:UniProtKB-KW:KW-0964), KNG1 HPX GP2 GC A1BG A2M DAG1 TTR PLG APOA4 B4GALT1 PGLYRP1 CATHL6 AZGP1 KNG2 CLU SPP1 FOLR1 SERPINC1 FGA CD14 LBP SERPINA1 SCGB1D CFB FGG CATHL1 RNASE4 CSN1S1 LPL C3 CRISP3 LGB CSN1S2 HP F2 NPC2 CTSB CHI3L1 ITIH1 PTGDS C6 PSAP AHSG SERPINF2 SERPINF1 ALB APOA1 LTF C7 CLEC3B ITIH4 CSN2 FGFBP1 FGB LALBA XDH NUCB1 PPIA MFGE8 LPO FN1 C9 PIGR CFD APOE ORM1 CFH CATHL2 B2M,CC,70,70 of 300,69.31,23.33,2.107E-91,1.397E-88
GO:0005615,extracellular space,A6QPP2(Evidence code:IEA/Database source:InterPro:IPR000215)Q2KIS7(Evidence code:ISS/Database source:UniProtKB:P05452)P30922(Evidence code:IEA/Database source:InterPro:IPR028538)Q1JPB0(Evidence code:IEA/Database source:InterPro:IPR000215)Q2UVX4(Evidence code:IEA/Database source:InterPro:IPR011626)Q0VCX1(Evidence code:IBA/Database source:PANTHER:PTN002385416)O18738(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P00711(Evidence code:IDA/Database source:)P07589(Evidence code:IDA/Database source:)Q3MHN2(Evidence code:ISS/Database source:UniProtKB:P02748)P02666(Evidence code:IEA/Database source:UniProtKB:P05814|ens)P80457(Evidence code:IDA/Database source:)Q3ZCH5(Evidence code:IEA/Database source:UniProtKB:P25311|ens)Q2KIF2(Evidence code:IEA/Database source:UniProtKB:P02750|ens)P34955(Evidence code:IEA/Database source:InterPro:IPR000215)P10790(Evidence code:IEA/Database source:UniProtKB:P11404|ens)P01045(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P01044(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q3MHN5(Evidence code:IEA/Database source:InterPro:IPR000213|I)O46375(Evidence code:IBA/Database source:PANTHER:PTN000044593)Q2TBI0(Evidence code:IEA/Database source:InterPro:IPR030180|I)P41361(Evidence code:IEA/Database source:InterPro:IPR000215)O02853(Evidence code:ISS/Database source:UniProtKB:P41222)P24627(Evidence code:IEA/Database source:InterPro:IPR016357)P02663(Evidence code:IDA/Database source:)G8JKW7(Evidence code:IEA/Database source:InterPro:IPR000215)P79345(Evidence code:IEA/Database source:UniProtKB:P61916|ens)P00735(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P30931(Evidence code:ISS/Database source:UniProtKB:P13726)P02769(Evidence code:IEA/Database source:InterPro:IPR000264|I)Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens)P17697(Evidence code:ISS/Database source:UniProtKB:P10909)P02662(Evidence code:IDA/Database source:)F1MX50(Evidence code:IEA/Database source:UniProtKB:O75629|ens)P08037(Evidence code:IDA/Database source:)P31096(Evidence code:IEA/Database source:UniProtKB-KW:KW-0202)P26779(Evidence code:IBA/Database source:PANTHER:PTN000159337)Q7SIH1(Evidence code:IEA/Database source:InterPro:IPR011626)Q95121(Evidence code:IEA/Database source:InterPro:IPR000215)P80025(Evidence code:IEA/Database source:UniProtKB:P22079|ens)Q3SZV7(Evidence code:IEA/Database source:UniProtKB:P02790|ens)P12763(Evidence code:IEA/Database source:InterPro:IPR001363)Q8WML4(Evidence code:IBA/Database source:PANTHER:PTN001293623)Q2TBU0(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q3SZR3(Evidence code:IEA/Database source:InterPro:IPR001500)P28800(Evidence code:IEA/Database source:InterPro:IPR000215)Q9MZ06(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P07688(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P11151(Evidence code:ISS/Database source:UniProtKB:P06858)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), SERPIND1 CLEC3B CHI3L1 SERPINB1 C3 C1S DAG1 LALBA FN1 C9 CSN2 XDH AZGP1 LRG1 SERPINA1 FABP3 KNG2 KNG1 GC TTR LBP SERPINC1 PTGDS LTF CSN1S2 SERPINA3 NPC2 F2 F3 ALB IGJ CLU CSN1S1 CREG1 B4GALT1 SPP1 PSAP A2M SERPINF1 LPO HPX AHSG MUC1 HP ORM1 SERPINF2 FGFBP1 CTSB LPL APOA1,CC,50,50 of 426,49.5,11.74,6.354E-54,2.106E-51
GO:0010951,negative regulation of endopeptidase activity,G8JKW7(Evidence code:IEA/Database source:GO:0004867)Q1JPB0(Evidence code:IEA/Database source:GO:0004867)P41361(Evidence code:IEA/Database source:GO:0004867)Q95121(Evidence code:IEA/Database source:GO:0004867)P01045(Evidence code:IEA/Database source:GO:0004869)A6QPP2(Evidence code:IEA/Database source:GO:0004867)Q7SIH1(Evidence code:IEA/Database source:GO:0004866)Q0VCM5(Evidence code:IEA/Database source:GO:0004867)Q2UVX4(Evidence code:IEA/Database source:GO:0004866)P34955(Evidence code:IEA/Database source:GO:0004867)P28800(Evidence code:IEA/Database source:GO:0004867)P01044(Evidence code:IEA/Database source:GO:0004869)Q3T052(Evidence code:IEA/Database source:GO:0004867)P12763(Evidence code:IEA/Database source:GO:0004866), SERPINA3 SERPINB1 SERPINC1 SERPINF1 KNG2 SERPIND1 A2M ITIH1 C3 SERPINA1 SERPINF2 KNG1 ITIH4 AHSG,BP,14,14 of 31,13.86,45.16,3.297E-24,7.286E-22
GO:0045087,innate immune response,Q28085(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)Q2TBI0(Evidence code:IEA/Database source:InterPro:IPR030180)Q0VCX1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)P02676(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)Q2UVX4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)Q29RU4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)P02672(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)Q8SPP7(Evidence code:IEA/Database source:InterPro:IPR017331)Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens)Q29RQ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)Q3T0A3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)Q95122(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399)P81187(Evidence code:IEA/Database source:UniProtKB-KW:KW-0399), CFH LBP C1S FGB C3 C9 C6 FGA PGLYRP1 IGJ C7 CFD CD14 CFB,BP,14,14 of 131,13.86,10.69,1.543E-16,2.557E-14
GO:0010466,negative regulation of peptidase activity,P02666(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P28800(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)Q1JPB0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)Q7SIH1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)Q0VCM5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P34955(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P41361(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)Q3T052(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646), CSN2 SERPINF2 SERPINB1 A2M KNG2 KNG1 ITIH1 SERPINA1 SERPINC1 ITIH4,BP,10,10 of 32,9.9,31.25,1.942E-16,2.576E-14
GO:0004867,serine-type endopeptidase inhibitor activity,Q7SIH1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0722)P41361(Evidence code:IEA/Database source:InterPro:IPR015555|I)A6QPP2(Evidence code:IBA/Database source:PANTHER:PTN000156122)P34955(Evidence code:IEA/Database source:UniProtKB-KW:KW-0722)G8JKW7(Evidence code:IBA/Database source:PANTHER:PTN000156122)Q3T052(Evidence code:IEA/Database source:InterPro:IPR010600)P28800(Evidence code:IEA/Database source:InterPro:IPR033833)Q0VCM5(Evidence code:IEA/Database source:InterPro:IPR010600)Q1JPB0(Evidence code:IEA/Database source:InterPro:IPR015557)Q95121(Evidence code:IBA/Database source:PANTHER:PTN000156122), A2M SERPINC1 SERPIND1 SERPINA1 SERPINA3 ITIH4 SERPINF2 ITIH1 SERPINB1 SERPINF1,MF,10,10 of 43,9.9,23.26,2.487E-15,2.748E-13
GO:0006953,acute-phase response,Q2TBI0(Evidence code:IEA/Database source:InterPro:IPR030180)Q3T052(Evidence code:IEA/Database source:UniProtKB-KW:KW-0011)Q3SZR3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0011)Q2TBU0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0011)P00735(Evidence code:IEA/Database source:UniProtKB-KW:KW-0011)P12763(Evidence code:ISS/Database source:UniProtKB:P02765)P07589(Evidence code:IEA/Database source:UniProtKB-KW:KW-0011)P28800(Evidence code:IEA/Database source:UniProtKB-KW:KW-0011), LBP ITIH4 ORM1 HP F2 AHSG FN1 SERPINF2,BP,8,8 of 16,7.92,50,8.806E-15,8.34E-13
GO:0007596,blood coagulation,P02676(Evidence code:IEA/Database source:InterPro:IPR037580)P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0094)P02672(Evidence code:IEA/Database source:InterPro:IPR037579)P00735(Evidence code:IEA/Database source:InterPro:IPR003966|I)P30931(Evidence code:IEA/Database source:InterPro:IPR001187)P41361(Evidence code:IEA/Database source:UniProtKB-KW:KW-0094)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0094)P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0094)P12799(Evidence code:IEA/Database source:InterPro:IPR037581), FGB PLG FGA F2 F3 SERPINC1 KNG2 KNG1 FGG,BP,9,9 of 31,8.91,29.03,1.06E-14,8.781E-13
GO:0007599,hemostasis,P00735(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P41361(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P02672(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P02676(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P30931(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P12799(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356)P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0356), F2 SERPINC1 FGA KNG1 FGB F3 KNG2 FGG PLG,BP,9,9 of 32,8.91,28.12,1.353E-14,9.97E-13
GO:0002376,immune system process,Q28085(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q3T0A3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q8SPP7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q95122(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)P81187(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)P02676(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q29RQ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q2UVX4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q2TBI0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q0VCX1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q2TBU0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)P01888(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)Q29RU4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391)P02672(Evidence code:IEA/Database source:UniProtKB-KW:KW-0391), CFH CFD PGLYRP1 CD14 CFB C9 FGB C7 C3 LTF LBP C1S HP B2M C6 FGA,BP,16,16 of 334,15.84,4.79,1.551E-13,1.028E-11
GO:0030414,peptidase inhibitor activity,Q7SIH1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P02666(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P28800(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)Q1JPB0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P34955(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)Q0VCM5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)Q3T052(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646)P41361(Evidence code:IEA/Database source:UniProtKB-KW:KW-0646), A2M KNG1 CSN2 KNG2 SERPINF2 SERPINB1 SERPINA1 ITIH1 ITIH4 SERPINC1,MF,10,10 of 80,9.9,12.5,6.496E-13,3.915E-11
GO:0006957,"complement activation, alternative pathway",Q28085(Evidence code:IEA/Database source:UniProtKB-KW:KW-0179)Q29RQ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0179)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0179)P81187(Evidence code:IEA/Database source:UniProtKB-KW:KW-0179)Q2UVX4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0179)Q3T0A3(Evidence code:IEA/Database source:InterPro:IPR037561), CFH C7 C9 CFB C3 CFD,BP,6,6 of 7,5.94,85.71,1.887E-12,1.042E-10
GO:0042742,defense response to bacterium,P80025(Evidence code:IEA/Database source:InterPro:IPR029587)P22226(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044)P19660(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044)Q2TBU0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044)Q8SPP7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044)P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044)P02663(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044)Q2TBI0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044)P54228(Evidence code:IEA/Database source:UniProtKB-KW:KW-0044), LPO CATHL1 CATHL2 HP PGLYRP1 LTF CSN1S2 LBP CATHL6,BP,9,9 of 86,8.91,10.47,3.844E-11,1.961E-09
GO:0004252,serine-type endopeptidase activity,P30931(Evidence code:IEA/Database source:UniProtKB:P13726|ens)Q3T0A3(Evidence code:IEA/Database source:InterPro:IPR001254|I)P81187(Evidence code:IEA/Database source:InterPro:IPR001254|I)Q32PI4(Evidence code:IEA/Database source:InterPro:IPR001254|I)P24627(Evidence code:IEA/Database source:InterPro:IPR030684)Q0VCX1(Evidence code:IEA/Database source:InterPro:IPR001254|I)P00735(Evidence code:IEA/Database source:InterPro:IPR001254|I)P06868(Evidence code:IEA/Database source:InterPro:IPR001254|I), F3 CFD CFB CFI LTF C1S F2 PLG,MF,8,8 of 57,7.92,14.04,5.341E-11,2.529E-09
GO:0042632,cholesterol homeostasis,P10790(Evidence code:IEA/Database source:UniProtKB:P11404|ens)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)P79345(Evidence code:IEA/Database source:UniProtKB:P61916|ens)P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens), FABP3 APOA4 APOA1 APOE NPC2 LPL,BP,6,6 of 19,5.94,31.58,1.882E-10,8.317E-09
GO:0005794,Golgi apparatus,Q3ZBZ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0333)P02663(Evidence code:IDA/Database source:)P08037(Evidence code:ISS/Database source:UniProtKB:P15291)P02662(Evidence code:IDA/Database source:)O02853(Evidence code:ISS/Database source:UniProtKB:P22057)P26201(Evidence code:ISS/Database source:UniProtKB:P16671)P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens)P12763(Evidence code:IEA/Database source:UniProtKB:P02765|ens)Q0P569(Evidence code:IEA/Database source:UniProtKB-KW:KW-0333)Q95122(Evidence code:ISS/Database source:UniProtKB:P08571)P02666(Evidence code:IDA/Database source:), SDF4 CSN1S2 B4GALT1 CSN1S1 PTGDS CD36 B2M AHSG NUCB1 CD14 CSN2,CC,11,11 of 202,10.89,5.45,2.091E-10,8.57E-09
GO:0005509,calcium ion binding,P02666(Evidence code:IBA/Database source:PANTHER:PTN000161175)Q0IIH5(Evidence code:IEA/Database source:InterPro:IPR002048|I)P00735(Evidence code:IEA/Database source:InterPro:IPR000294|I)Q0VCX1(Evidence code:IEA/Database source:InterPro:IPR001881|I)Q0P569(Evidence code:IEA/Database source:InterPro:IPR002048)P80025(Evidence code:IDA/Database source:)Q3SX14(Evidence code:IEA/Database source:InterPro:IPR030004)P00711(Evidence code:IEA/Database source:InterPro:IPR000545)O18738(Evidence code:IEA/Database source:InterPro:IPR015919)Q2KIS7(Evidence code:ISS/Database source:UniProtKB:P05452)Q3ZBZ1(Evidence code:IEA/Database source:InterPro:IPR002048), CSN2 NUCB2 F2 C1S NUCB1 LPO GSN LALBA DAG1 CLEC3B SDF4,MF,11,11 of 203,10.89,5.42,2.197E-10,8.57E-09
GO:0008201,heparin binding,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens)P07589(Evidence code:IEA/Database source:UniProtKB-KW:KW-0358)Q2KIS7(Evidence code:ISS/Database source:UniProtKB:P05452)P11151(Evidence code:ISS/Database source:UniProtKB:P06858)P41361(Evidence code:IEA/Database source:InterPro:IPR015555)Q03247(Evidence code:IEA/Database source:UniProtKB-KW:KW-0358), LTF F2 FN1 CLEC3B LPL SERPINC1 APOE,MF,7,7 of 52,6.93,13.46,1.094E-09,4.03E-08
GO:0005886,plasma membrane,Q3MHN2(Evidence code:ISS/Database source:UniProtKB:P02748)P12763(Evidence code:TAS/Database source:)O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)Q9MZ06(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)Q3ZCH5(Evidence code:IBA/Database source:PANTHER:PTN000422281)P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens)P26201(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)Q95122(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)P30931(Evidence code:IBA/Database source:PANTHER:PTN000466212)P60712(Evidence code:ISS/Database source:UniProtKB:G1NS52)P05307(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)Q8WML4(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)P08037(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)P02702(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003)P81265(Evidence code:IEA/Database source:UniProtKB-KW:KW-1003), C9 AHSG DAG1 FGFBP1 LPL AZGP1 B2M CD36 CD14 F3 ACTB P4HB MUC1 B4GALT1 FOLR1 PIGR,CC,16,16 of 630,15.84,2.54,1.221E-09,4.262E-08
GO:0072562,blood microparticle,Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)P01045(Evidence code:IBA/Database source:PANTHER:PTN001790518)P01044(Evidence code:IBA/Database source:PANTHER:PTN001790518)P15497(Evidence code:IBA/Database source:PANTHER:PTN000439006)P12763(Evidence code:IBA/Database source:PANTHER:PTN000352259), APOA4 APOE KNG2 KNG1 APOA1 AHSG,CC,6,6 of 31,5.94,19.35,2.387E-09,7.913E-08
GO:0006958,"complement activation, classical pathway",Q29RU4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0180)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0180)Q2UVX4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0180)Q29RQ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0180)Q0VCX1(Evidence code:IEA/Database source:InterPro:IPR035708), C6 C9 C3 C7 C1S,BP,5,5 of 15,4.95,33.33,5.056E-09,1.596E-07
GO:0008236,serine-type peptidase activity,Q0VCX1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0720)Q3T0A3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0720)P00735(Evidence code:IEA/Database source:UniProtKB-KW:KW-0720)P81187(Evidence code:IEA/Database source:UniProtKB-KW:KW-0720)P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0720)P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0720)Q32PI4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0720), C1S CFD F2 CFB PLG LTF CFI,MF,7,7 of 67,6.93,10.45,5.523E-09,1.665E-07
GO:0005623,cell,Q32P72(Evidence code:IEA/Database source:GO:0006879)Q3SZV7(Evidence code:IEA/Database source:GO:0006879)P01045(Evidence code:IEA/Database source:GO:0007204)P01044(Evidence code:IEA/Database source:GO:0007204)A6QQA8(Evidence code:IEA/Database source:GO:0045454), CP HPX KNG2 KNG1 QSOX1,CC,5,5 of 16,4.95,31.25,6.618E-09,1.908E-07
GO:0034372,very-low-density lipoprotein particle remodeling,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens)P15497(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006), LPL APOA1 APOE APOA4,BP,4,4 of 4,3.96,100,7.2E-09,1.909E-07
GO:0005577,fibrinogen complex,P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens)P02676(Evidence code:IEA/Database source:InterPro:IPR012290)P02672(Evidence code:IEA/Database source:InterPro:IPR012290)P12799(Evidence code:IEA/Database source:InterPro:IPR012290), SERPINF2 FGB FGA FGG,CC,4,4 of 4,3.96,100,7.2E-09,1.909E-07
GO:1903496,response to 11-deoxycorticosterone,P02666(Evidence code:IDA/Database source:)P02663(Evidence code:IDA/Database source:)P00711(Evidence code:IDA/Database source:)P02662(Evidence code:IDA/Database source:), CSN2 CSN1S2 LALBA CSN1S1,BP,4,4 of 5,3.96,80,1.293E-08,3.061E-07
GO:0098869,cellular oxidant detoxification,P02662(Evidence code:IEA/Database source:GO:0016209)Q2TBU0(Evidence code:IEA/Database source:GO:0016209)P80025(Evidence code:IEA/Database source:GO:0004601)P02666(Evidence code:IEA/Database source:GO:0016209), CSN1S1 HP LPO CSN2,BP,4,4 of 5,3.96,80,1.293E-08,3.061E-07
GO:1903494,response to dehydroepiandrosterone,P00711(Evidence code:IDA/Database source:)P02663(Evidence code:IDA/Database source:)P02666(Evidence code:IDA/Database source:)P02662(Evidence code:IDA/Database source:), LALBA CSN1S2 CSN2 CSN1S1,BP,4,4 of 5,3.96,80,1.293E-08,3.061E-07
GO:0005796,Golgi lumen,P02662(Evidence code:IDA/Database source:)Q3ZBZ1(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P02663(Evidence code:IDA/Database source:)P02666(Evidence code:IDA/Database source:), CSN1S1 SDF4 CSN1S2 CSN2,CC,4,4 of 6,3.96,66.67,2.149E-08,4.748E-07
GO:0017127,cholesterol transporter activity,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)P79345(Evidence code:IEA/Database source:UniProtKB:P61916|ens)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006), APOA1 APOE NPC2 APOA4,MF,4,4 of 6,3.96,66.67,2.149E-08,4.748E-07
GO:0042627,chylomicron,Q03247(Evidence code:IEA/Database source:UniProtKB-KW:KW-0162)P15497(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0162)P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-0162), APOE APOA1 APOA4 LPL,CC,4,4 of 7,3.96,57.14,3.368E-08,6.977E-07
GO:0019433,triglyceride catabolic process,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)P15497(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens), APOE APOA1 APOA4 LPL,BP,4,4 of 7,3.96,57.14,3.368E-08,6.977E-07
GO:0005737,cytoplasm,Q2KIS7(Evidence code:ISS/Database source:UniProtKB:P05452)Q9XSG3(Evidence code:ISS/Database source:UniProtKB:O75874)O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)P60712(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)P26779(Evidence code:IBA/Database source:PANTHER:PTN001352635)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)P10790(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)Q0P569(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)Q3SX14(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)Q0IIH5(Evidence code:IEA/Database source:UniProtKB:P81117|ens)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)Q8WML4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)Q1JPB0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)P30922(Evidence code:ISS/Database source:UniProtKB:Q61362)P62935(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)P80025(Evidence code:IEA/Database source:UniProtKB:Q5SW46|ens)P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)P80457(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963)Q3T0Q4(Evidence code:ISS/Database source:UniProtKB:P22392)A6H7B5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0963), CLEC3B IDH1 DAG1 ACTB PSAP LTF FABP3 NUCB1 GSN NUCB2 PTGDS MUC1 SERPINB1 CHI3L1 PPIA LPO CLU XDH NME2 COPS3,CC,20,20 of 1304,19.8,1.53,5.288E-08,0.000001048
GO:0004869,cysteine-type endopeptidase inhibitor activity,P01044(Evidence code:IEA/Database source:InterPro:IPR000010)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)P01045(Evidence code:IEA/Database source:InterPro:IPR000010)P12763(Evidence code:IEA/Database source:InterPro:IPR000010)P02666(Evidence code:IEA/Database source:UniProtKB:P05814|ens), KNG1 LTF KNG2 AHSG CSN2,MF,5,5 of 26,4.95,19.23,5.376E-08,0.000001048
GO:0016020,membrane,P05307(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q9MZ06(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)G3N2D8(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q95122(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)P02702(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)P08037(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q95114(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q0P569(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q9TUM6(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q2TBI0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)F1N514(Evidence code:IEA/Database source:InterPro:IPR001190|I)P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)P80195(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)P81265(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04264|ens)P30931(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)P26201(Evidence code:IEA/Database source:InterPro:IPR002159)P18892(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)Q32PI4(Evidence code:IEA/Database source:InterPro:IPR001190|I)Q8WML4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0472)O18738(Evidence code:IEA/Database source:InterPro:IPR006644|I), P4HB FGFBP1 GGT1 CD14 FOLR1 B4GALT1 MFGE8 PTGDS NUCB1 PLIN2 LBP CD5L LPL CLU GLYCAM1 PIGR C9 KRT1 F3 CD36 BTN1A1 CFI MUC1 DAG1,CC,24,24 of 1837,23.76,1.31,5.911E-08,0.00000112
GO:0033344,cholesterol efflux,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)P79345(Evidence code:ISS/Database source:UniProtKB:Q9Z0J0)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), APOE APOA4 NPC2 APOA1,BP,4,4 of 9,3.96,44.44,7.258E-08,0.000001301
GO:0032570,response to progesterone,P02663(Evidence code:IDA/Database source:)P02662(Evidence code:IDA/Database source:)P02666(Evidence code:IDA/Database source:)P00711(Evidence code:IDA/Database source:), CSN1S2 CSN1S1 CSN2 LALBA,BP,4,4 of 9,3.96,44.44,7.258E-08,0.000001301
GO:0005783,endoplasmic reticulum,Q0VCX2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0256)Q0IIH5(Evidence code:IEA/Database source:UniProtKB:P81117|ens)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0256)P30922(Evidence code:ISS/Database source:UniProtKB:Q61362)P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0256)Q32KV6(Evidence code:IEA/Database source:UniProtKB-KW:KW-0256)P05307(Evidence code:ISS/Database source:UniProtKB:P07237)Q3MHX6(Evidence code:IEA/Database source:UniProtKB-KW:KW-0256)P79345(Evidence code:IEA/Database source:UniProtKB-KW:KW-0256), HSPA5 NUCB2 PTGDS CHI3L1 CLU SIL1 P4HB OS9 NPC2,CC,9,9 of 220,8.91,4.09,8.84E-08,0.000001542
GO:0006508,proteolysis,P06868(Evidence code:IEA/Database source:InterPro:IPR001254|I)Q3T0A3(Evidence code:IEA/Database source:InterPro:IPR001254|I)P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)G3N2D8(Evidence code:IEA/Database source:GO:0036374)Q32PI4(Evidence code:IEA/Database source:InterPro:IPR001254|I)P81187(Evidence code:IEA/Database source:InterPro:IPR001254|I)P00735(Evidence code:IEA/Database source:InterPro:IPR001254|I)P07688(Evidence code:IEA/Database source:InterPro:IPR000668)Q0VCX1(Evidence code:IEA/Database source:InterPro:IPR001254|I), PLG CFD LTF GGT1 CFI CFB F2 CTSB C1S,BP,9,9 of 230,8.91,3.91,1.268E-07,0.000002156
GO:0015485,cholesterol binding,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P79345(Evidence code:ISS/Database source:UniProtKB:P61916), APOE APOA4 APOA1 NPC2,MF,4,4 of 12,3.96,33.33,1.833E-07,0.000003038
GO:0030168,platelet activation,P02676(Evidence code:IEA/Database source:InterPro:IPR012290)P12799(Evidence code:IEA/Database source:InterPro:IPR012290)P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens)P02672(Evidence code:IEA/Database source:InterPro:IPR012290), FGB FGG F2 FGA,BP,4,4 of 13,3.96,30.77,2.391E-07,0.000003774
GO:0032355,response to estradiol,P02663(Evidence code:IDA/Database source:)P00711(Evidence code:IDA/Database source:)P02666(Evidence code:IDA/Database source:)P02662(Evidence code:IDA/Database source:), CSN1S2 LALBA CSN2 CSN1S1,BP,4,4 of 13,3.96,30.77,2.391E-07,0.000003774
GO:0019835,cytolysis,Q29RQ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0204)P22226(Evidence code:IMP/Database source:)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0204)Q29RU4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0204), C7 CATHL1 C9 C6,BP,4,4 of 17,3.96,23.53,0.000000595,0.000009174
GO:0008233,peptidase activity,Q3T0A3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)P81187(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)Q0VCX1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)P07688(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)P00735(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645)Q32PI4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0645), CFD PLG LTF CFB C1S CTSB F2 CFI,MF,8,8 of 205,7.92,3.9,6.249E-07,0.000009386
GO:0005579,membrane attack complex,Q29RQ1(Evidence code:IEA/Database source:InterPro:IPR001862|I)Q29RU4(Evidence code:IEA/Database source:InterPro:IPR001862|I)Q3MHN2(Evidence code:IEA/Database source:InterPro:IPR001862|I), C7 C6 C9,CC,3,3 of 3,2.97,100,6.371E-07,0.000009386
GO:0006956,complement activation,Q29RU4(Evidence code:IEA/Database source:InterPro:IPR037563)Q2UVX4(Evidence code:IEA/Database source:InterPro:IPR001840|I)P81187(Evidence code:IEA/Database source:InterPro:IPR011360)Q29RQ1(Evidence code:IEA/Database source:InterPro:IPR037564), C6 C3 CFB C7,BP,4,4 of 19,3.96,21.05,8.757E-07,0.00001262
GO:0060228,phosphatidylcholine-sterol O-acyltransferase activator activity,Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), APOA4 APOE APOA1,MF,3,3 of 4,2.97,75,0.000001112,0.00001505
GO:0034380,high-density lipoprotein particle assembly,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006), APOA1 APOE APOA4,BP,3,3 of 4,2.97,75,0.000001112,0.00001505
GO:0010873,positive regulation of cholesterol esterification,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), APOE APOA4 APOA1,BP,3,3 of 4,2.97,75,0.000001112,0.00001505
GO:0019731,antibacterial humoral response,Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens)P24627(Evidence code:IEA/Database source:InterPro:IPR030684)P80025(Evidence code:IDA/Database source:), IGJ LTF LPO,BP,3,3 of 5,2.97,60,0.000001775,0.00002308
GO:0043691,reverse cholesterol transport,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006), APOA1 APOE APOA4,BP,3,3 of 5,2.97,60,0.000001775,0.00002308
GO:0051258,protein polymerization,P00735(Evidence code:IDA/Database source:)P02672(Evidence code:IEA/Database source:InterPro:IPR012290)P02676(Evidence code:IEA/Database source:InterPro:IPR012290)P12799(Evidence code:IEA/Database source:InterPro:IPR012290), F2 FGA FGB FGG,BP,4,4 of 24,3.96,16.67,0.000001999,0.00002548
GO:0007155,cell adhesion,Q95114(Evidence code:IEA/Database source:UniProtKB-KW:KW-0130)Q3ZCH5(Evidence code:IEA/Database source:UniProtKB:P25311|ens)P07589(Evidence code:IEA/Database source:UniProtKB-KW:KW-0130)P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens)P31096(Evidence code:IEA/Database source:InterPro:IPR002038|I)P26201(Evidence code:IEA/Database source:UniProtKB-KW:KW-0130)Q8WML4(Evidence code:IBA/Database source:PANTHER:PTN001293623), MFGE8 AZGP1 FN1 B4GALT1 SPP1 CD36 MUC1,BP,7,7 of 171,6.93,4.09,0.000002258,0.00002825
GO:0050728,negative regulation of inflammatory response,G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04104|ens)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O88593|ens)P02666(Evidence code:IDA/Database source:), KRT1 APOA1 PGLYRP1 CSN2,BP,4,4 of 27,3.96,14.81,0.000003047,0.00003741
GO:0042157,lipoprotein metabolic process,Q03247(Evidence code:IEA/Database source:InterPro:IPR000074)Q32PJ2(Evidence code:IEA/Database source:InterPro:IPR000074)P15497(Evidence code:IEA/Database source:InterPro:IPR000074), APOE APOA4 APOA1,BP,3,3 of 7,2.97,42.86,0.000003785,0.00004403
GO:0031102,neuron projection regeneration,P15497(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006), APOA1 APOE APOA4,BP,3,3 of 7,2.97,42.86,0.000003785,0.00004403
GO:0031210,phosphatidylcholine binding,P15497(Evidence code:IBA/Database source:PANTHER:PTN000439034)Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439034), APOA1 IGJ APOA4,MF,3,3 of 7,2.97,42.86,0.000003785,0.00004403
GO:0001503,ossification,P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0892)P12763(Evidence code:IEA/Database source:UniProtKB:P29699|ens)Q2KIS7(Evidence code:IEA/Database source:UniProtKB:P05452|ens)P31096(Evidence code:IEA/Database source:InterPro:IPR002038|I), LTF AHSG CLEC3B SPP1,BP,4,4 of 30,3.96,13.33,0.000004456,0.00005094
GO:0034361,very-low-density lipoprotein particle,Q03247(Evidence code:IEA/Database source:UniProtKB-KW:KW-0850)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-0850), APOE APOA1 LPL,CC,3,3 of 8,2.97,37.5,0.000005192,0.00005835
GO:0050829,defense response to Gram-negative bacterium,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)P00711(Evidence code:IBA/Database source:PANTHER:PTN001685984)P22226(Evidence code:IMP/Database source:)Q2TBI0(Evidence code:IEA/Database source:InterPro:IPR030180), LTF LALBA CATHL1 LBP,BP,4,4 of 32,3.96,12.5,0.000005631,0.00006222
GO:0033700,phospholipid efflux,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), APOE APOA4 APOA1,BP,3,3 of 9,2.97,33.33,0.000006906,0.00007385
GO:0001530,lipopolysaccharide binding,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens)Q2TBI0(Evidence code:IEA/Database source:InterPro:IPR030180)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens), F2 LBP LTF,MF,3,3 of 9,2.97,33.33,0.000006906,0.00007385
GO:0005788,endoplasmic reticulum lumen,P05307(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q32KV6(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q0VCX2(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q3MHX6(Evidence code:ISS/Database source:UniProtKB:Q13438), P4HB SIL1 HSPA5 OS9,CC,4,4 of 34,3.96,11.76,0.00000702,0.00007387
GO:0001540,amyloid-beta binding,Q03247(Evidence code:ISS/Database source:UniProtKB:P02649)P02662(Evidence code:IDA/Database source:)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), APOE CSN1S1 APOA1,MF,3,3 of 10,2.97,30,0.000008956,0.00009278
GO:0031640,killing of cells of other organism,P54228(Evidence code:IEA/Database source:UniProtKB-KW:KW-0295)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)Q8SPP7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0295), CATHL6 LTF PGLYRP1,BP,3,3 of 11,2.97,27.27,0.00001137,0.0001142
GO:0061844,antimicrobial humoral immune response mediated by antimicrobial peptide,Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O75594|ens)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens), PGLYRP1 LTF F2,BP,3,3 of 11,2.97,27.27,0.00001137,0.0001142
GO:0009897,external side of plasma membrane,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens)P08037(Evidence code:ISS/Database source:UniProtKB:P15291)P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens)Q95122(Evidence code:ISS/Database source:UniProtKB:P10810), B2M B4GALT1 F2 CD14,CC,4,4 of 39,3.96,10.26,0.00001158,0.0001146
GO:0034364,high-density lipoprotein particle,P15497(Evidence code:IEA/Database source:UniProtKB-KW:KW-0345)Q32PJ2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0345)Q03247(Evidence code:IEA/Database source:UniProtKB-KW:KW-0345), APOA1 APOA4 APOE,CC,3,3 of 13,2.97,23.08,0.00001741,0.0001697
GO:0009986,cell surface,P11151(Evidence code:IEA/Database source:UniProtKB:P11152|ens)P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens)P08037(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P30931(Evidence code:ISS/Database source:UniProtKB:P13726)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens), LPL SERPINF2 B4GALT1 F3 LTF,CC,5,5 of 94,4.95,5.32,0.00001879,0.0001805
GO:0070328,triglyceride homeostasis,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439034)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), LPL APOA4 APOA1,BP,3,3 of 14,2.97,21.43,0.00002109,0.0001997
GO:0006869,lipid transport,Q03247(Evidence code:IEA/Database source:InterPro:IPR000074)Q2TBI0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0445)P15497(Evidence code:IEA/Database source:InterPro:IPR000074)Q32PJ2(Evidence code:IEA/Database source:InterPro:IPR000074), APOE LBP APOA1 APOA4,BP,4,4 of 51,3.96,7.84,0.00003103,0.0002897
GO:0006695,cholesterol biosynthetic process,Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439006)P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006), APOA4 APOA1 APOE,BP,3,3 of 17,2.97,17.65,0.0000351,0.0003232
GO:0046872,metal ion binding,Q3ZBZ1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)P02769(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)Q3SX14(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)P08037(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)Q9XSG3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)Q0P569(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)Q3SZV7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)P80457(Evidence code:IEA/Database source:InterPro:IPR002888)P80025(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)P12799(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)Q0VCX1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479)P00711(Evidence code:IEA/Database source:UniProtKB-KW:KW-0479), SDF4 ALB GSN B4GALT1 IDH1 NUCB1 HPX XDH LPO FGG NME2 C1S LTF LALBA,MF,14,14 of 1125,13.86,1.24,0.00003662,0.0003326
GO:0008289,lipid binding,P02769(Evidence code:IEA/Database source:UniProtKB-KW:KW-0446)Q32PJ2(Evidence code:IEA/Database source:InterPro:IPR000074)P10790(Evidence code:IEA/Database source:InterPro:IPR000463|I)Q2TBI0(Evidence code:IEA/Database source:InterPro:IPR001124|I)P15497(Evidence code:IEA/Database source:InterPro:IPR000074)Q03247(Evidence code:IEA/Database source:InterPro:IPR000074), ALB APOA4 FABP3 LBP APOA1 APOE,MF,6,6 of 190,5.94,3.16,0.00004771,0.0004274
GO:0005102,signaling receptor binding,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens)P24627(Evidence code:IMP/Database source:)P02676(Evidence code:IEA/Database source:InterPro:IPR012290)P12799(Evidence code:IEA/Database source:InterPro:IPR012290)P06868(Evidence code:IPI/Database source:UniProtKB:P08169)P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens)Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens)P02672(Evidence code:IEA/Database source:InterPro:IPR012290), F2 LTF FGB FGG PLG LPL A2M FGA,MF,8,8 of 385,7.92,2.08,0.00005237,0.000463
GO:0006954,inflammatory response,Q95122(Evidence code:IEA/Database source:UniProtKB-KW:KW-0395)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0395)P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0395)P30922(Evidence code:ISS/Database source:UniProtKB:P36222)Q2UVX4(Evidence code:IEA/Database source:InterPro:IPR001840), CD14 KNG2 KNG1 CHI3L1 C3,BP,5,5 of 121,4.95,4.13,0.0000596,0.000489
GO:0042834,peptidoglycan binding,Q8SPP7(Evidence code:IEA/Database source:InterPro:IPR017331)Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens), PGLYRP1 IGJ,MF,2,2 of 2,1.98,100,0.00005975,0.000489
GO:0004461,lactose synthase activity,P00711(Evidence code:IEA/Database source:InterPro:IPR000545)P08037(Evidence code:IEA/Database source:EC:2.4.1.22), LALBA B4GALT1,MF,2,2 of 2,1.98,100,0.00005975,0.000489
GO:0044218,other organism cell membrane,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-1052), LTF C9,CC,2,2 of 2,1.98,100,0.00005975,0.000489
GO:0055091,phospholipid homeostasis,P10790(Evidence code:IEA/Database source:UniProtKB:P11404|ens)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), FABP3 APOA1,BP,2,2 of 2,1.98,100,0.00005975,0.000489
GO:0005989,lactose biosynthetic process,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens)P00711(Evidence code:IEA/Database source:InterPro:IPR000545), B4GALT1 LALBA,BP,2,2 of 2,1.98,100,0.00005975,0.000489
GO:0042803,protein homodimerization activity,P02663(Evidence code:IDA/Database source:)P08037(Evidence code:ISS/Database source:UniProtKB:P15291-1)P80457(Evidence code:IDA/Database source:)P02666(Evidence code:IDA/Database source:)P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens)Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens), CSN1S2 B4GALT1 XDH CSN2 SERPINF2 IGJ,MF,6,6 of 210,5.94,2.86,0.00008137,0.0006579
GO:0030300,regulation of intestinal cholesterol absorption,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439034), APOA1 APOA4,BP,2,2 of 3,1.98,66.67,0.00009936,0.000766
GO:0001867,"complement activation, lectin pathway",Q0VCX1(Evidence code:IBA/Database source:PANTHER:PTN002385419)G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04264|ens), C1S KRT1,BP,2,2 of 3,1.98,66.67,0.00009936,0.000766
GO:0044539,long-chain fatty acid import,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857)P10790(Evidence code:IEA/Database source:UniProtKB:P11404|ens), CD36 FABP3,BP,2,2 of 3,1.98,66.67,0.00009936,0.000766
GO:0010804,negative regulation of tumor necrosis factor-mediated signaling pathway,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P02666(Evidence code:IDA/Database source:), APOA1 CSN2,BP,2,2 of 3,1.98,66.67,0.00009936,0.000766
GO:0030246,carbohydrate binding,Q2KIS7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0430)G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04264|ens)P30922(Evidence code:IEA/Database source:UniProtKB-KW:KW-0430)Q3MHX6(Evidence code:IEA/Database source:UniProtKB-KW:KW-0430), CLEC3B KRT1 CHI3L1 OS9,MF,4,4 of 73,3.96,5.48,0.0001163,0.0008861
GO:0016787,hydrolase activity,Q0VCX1(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)P07688(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)P81187(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)Q3T0A3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)Q32PI4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)Q0VCX2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)P00735(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378)P15467(Evidence code:IEA/Database source:UniProtKB-KW:KW-0378), C1S CTSB CFB CFD CFI LPL LTF PLG HSPA5 F2 RNASE4,MF,11,11 of 836,10.89,1.32,0.0001391,0.001048
GO:0001580,detection of chemical stimulus involved in sensory perception of bitter taste,Q3ZCH5(Evidence code:IEA/Database source:UniProtKB:P25311|ens)P80025(Evidence code:IEA/Database source:UniProtKB:P22079|ens), AZGP1 LPO,BP,2,2 of 4,1.98,50,0.0001487,0.00106
GO:0051006,positive regulation of lipoprotein lipase activity,Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439034)P15497(Evidence code:IBA/Database source:PANTHER:PTN000439034), APOA4 APOA1,BP,2,2 of 4,1.98,50,0.0001487,0.00106
GO:0031362,anchored component of external side of plasma membrane,P02702(Evidence code:ISS/Database source:UniProtKB:P15328)Q95122(Evidence code:ISS/Database source:UniProtKB:P08571), FOLR1 CD14,CC,2,2 of 4,1.98,50,0.0001487,0.00106
GO:0071726,cellular response to diacyl bacterial lipopeptide,P26201(Evidence code:ISS/Database source:UniProtKB:P16671)Q95122(Evidence code:ISS/Database source:UniProtKB:P08571), CD36 CD14,BP,2,2 of 4,1.98,50,0.0001487,0.00106
GO:0070508,cholesterol import,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P26201(Evidence code:ISS/Database source:UniProtKB:Q08857), APOA1 CD36,BP,2,2 of 4,1.98,50,0.0001487,0.00106
GO:0045766,positive regulation of angiogenesis,P30931(Evidence code:ISS/Database source:UniProtKB:P13726)Q2KIF2(Evidence code:IEA/Database source:UniProtKB:Q91XL1|ens)P30922(Evidence code:IEA/Database source:InterPro:IPR028538), F3 LRG1 CHI3L1,BP,3,3 of 31,2.97,9.68,0.0001781,0.001243
GO:0050830,defense response to Gram-positive bacterium,P22226(Evidence code:IMP/Database source:)Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O75594|ens)P00711(Evidence code:IBA/Database source:PANTHER:PTN001685984), CATHL1 PGLYRP1 LALBA,BP,3,3 of 31,2.97,9.68,0.0001781,0.001243
GO:0010898,positive regulation of triglyceride catabolic process,Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439034)P15497(Evidence code:IBA/Database source:PANTHER:PTN000439034), APOA4 APOA1,BP,2,2 of 5,1.98,40,0.0002078,0.001406
GO:0034366,spherical high-density lipoprotein particle,P17697(Evidence code:ISS/Database source:UniProtKB:P10909)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), CLU APOA1,CC,2,2 of 5,1.98,40,0.0002078,0.001406
GO:0044793,negative regulation by host of viral process,O02853(Evidence code:IDA/Database source:)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens), PTGDS LTF,BP,2,2 of 5,1.98,40,0.0002078,0.001406
GO:0002020,protease binding,P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens)Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens)P30931(Evidence code:IEA/Database source:UniProtKB:P13726|ens), SERPINF2 A2M F3,MF,3,3 of 33,2.97,9.09,0.0002115,0.001416
GO:0055114,oxidation-reduction process,P80457(Evidence code:IEA/Database source:InterPro:IPR002346|I)P80025(Evidence code:IEA/Database source:InterPro:IPR010255)Q32P72(Evidence code:IEA/Database source:GO:0004322)Q9XSG3(Evidence code:IEA/Database source:InterPro:IPR004790|I)A6QQA8(Evidence code:IEA/Database source:InterPro:IPR017905|I), XDH LPO CP IDH1 QSOX1,BP,5,5 of 162,4.95,3.09,0.0002225,0.001475
GO:0031225,anchored component of membrane,P02702(Evidence code:IEA/Database source:UniProtKB-KW:KW-0336)Q95122(Evidence code:IEA/Database source:UniProtKB-KW:KW-0336)P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-0336), FOLR1 CD14 LPL,CC,3,3 of 34,2.97,8.82,0.0002296,0.001507
GO:0009617,response to bacterium,Q2KIF2(Evidence code:IEA/Database source:UniProtKB:Q91XL1|ens)P11151(Evidence code:IEA/Database source:UniProtKB:P11152|ens)Q95122(Evidence code:ISS/Database source:UniProtKB:P10810)Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O88593|ens), LRG1 LPL CD14 PGLYRP1,BP,4,4 of 92,3.96,4.35,0.0002717,0.001762
GO:0060416,response to growth hormone,P02663(Evidence code:IDA/Database source:)P02662(Evidence code:IDA/Database source:), CSN1S2 CSN1S1,BP,2,2 of 6,1.98,33.33,0.0002764,0.001762
GO:0032967,positive regulation of collagen biosynthetic process,P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens)P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens), SERPINF2 F2,BP,2,2 of 6,1.98,33.33,0.0002764,0.001762
GO:0016209,antioxidant activity,P02662(Evidence code:IEA/Database source:UniProtKB-KW:KW-0049)Q2TBU0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0049)P02666(Evidence code:IEA/Database source:UniProtKB-KW:KW-0049), CSN1S1 HP CSN2,MF,3,3 of 37,2.97,8.11,0.0002898,0.00183
GO:0051180,vitamin transport,Q3MHN5(Evidence code:IEA/Database source:InterPro:IPR000213)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), GC APOA1,BP,2,2 of 7,1.98,28.57,0.0003547,0.002177
GO:0045723,positive regulation of fatty acid biosynthetic process,P15497(Evidence code:IBA/Database source:PANTHER:PTN000439034)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439034), APOA1 APOA4,BP,2,2 of 7,1.98,28.57,0.0003547,0.002177
GO:0031526,brush border membrane,P26201(Evidence code:ISS/Database source:UniProtKB:Q07969)P08037(Evidence code:ISS/Database source:UniProtKB:P15291), CD36 B4GALT1,CC,2,2 of 7,1.98,28.57,0.0003547,0.002177
GO:0070374,positive regulation of ERK1 and ERK2 cascade,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857)P30922(Evidence code:ISS/Database source:UniProtKB:P36222)P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens), CD36 CHI3L1 SERPINF2,BP,3,3 of 42,2.97,7.14,0.0004112,0.002501
GO:0046470,phosphatidylcholine metabolic process,P15497(Evidence code:IBA/Database source:PANTHER:PTN000439034)Q32PJ2(Evidence code:IBA/Database source:PANTHER:PTN000439034), APOA1 APOA4,BP,2,2 of 8,1.98,25,0.0004424,0.002642
GO:0030212,hyaluronan metabolic process,Q3T052(Evidence code:IEA/Database source:InterPro:IPR010600)Q0VCM5(Evidence code:IEA/Database source:InterPro:IPR010600), ITIH4 ITIH1,BP,2,2 of 8,1.98,25,0.0004424,0.002642
GO:0007204,positive regulation of cytosolic calcium ion concentration,P01045(Evidence code:IBA/Database source:PANTHER:PTN001790518)P26201(Evidence code:ISS/Database source:UniProtKB:Q08857)P01044(Evidence code:IBA/Database source:PANTHER:PTN001790518), KNG2 CD36 KNG1,BP,3,3 of 44,2.97,6.82,0.0004677,0.002768
GO:0006879,cellular iron ion homeostasis,Q32P72(Evidence code:IEA/Database source:InterPro:IPR027150)Q3SZV7(Evidence code:IEA/Database source:InterPro:IPR016358), CP HPX,BP,2,2 of 9,1.98,22.22,0.0005395,0.003138
GO:0042311,vasodilation,P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0840)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0840), KNG1 KNG2,BP,2,2 of 9,1.98,22.22,0.0005395,0.003138
GO:0050821,protein stabilization,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P17697(Evidence code:ISS/Database source:UniProtKB:P10909)P02662(Evidence code:IDA/Database source:), APOA1 CLU CSN1S1,BP,3,3 of 47,2.97,6.38,0.0005612,0.003236
GO:0005515,protein binding,P08037(Evidence code:IPI/Database source:UniProtKB:P29752)P79345(Evidence code:IPI/Database source:UniProtKB:O35604)O02853(Evidence code:IPI/Database source:UniProtKB:P29128)P07589(Evidence code:IPI/Database source:UniProtKB:Q15113)Q3MHX6(Evidence code:ISS/Database source:UniProtKB:Q13438)P06868(Evidence code:IPI/Database source:UniProtKB:P43025)Q3T0Q4(Evidence code:IPI/Database source:UniProtKB:P62871)P11151(Evidence code:IPI/Database source:UniProtKB:Q99523)P60712(Evidence code:IPI/Database source:UniProtKB:Q4VW77)P02666(Evidence code:IPI/Database source:UniProtKB:O43464)P00735(Evidence code:IPI/Database source:UniProtKB:Q4W8J9)P12763(Evidence code:IPI/Database source:UniProtKB:P17931)P24627(Evidence code:IPI/Database source:UniProtKB:P27958:PRO)O18738(Evidence code:IPI/Database source:UniProtKB:P19137)P02676(Evidence code:IPI/Database source:UniProtKB:P23142), B4GALT1 NPC2 PTGDS FN1 OS9 PLG NME2 LPL ACTB CSN2 F2 AHSG LTF DAG1 FGB,MF,15,15 of 1669,14.85,0.9,0.0006,0.003429
GO:0042730,fibrinolysis,P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0280)P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens), PLG F2,BP,2,2 of 10,1.98,20,0.0006461,0.003661
GO:0002250,adaptive immune response,P02672(Evidence code:IEA/Database source:UniProtKB-KW:KW-1064)P02676(Evidence code:IEA/Database source:UniProtKB-KW:KW-1064)Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens), FGA FGB IGJ,BP,3,3 of 52,2.97,5.77,0.0007422,0.00417
GO:0006955,immune response,P01888(Evidence code:IEA/Database source:InterPro:IPR015707)Q3MHN2(Evidence code:IEA/Database source:InterPro:IPR001862)Q29RQ1(Evidence code:IEA/Database source:InterPro:IPR001862)P26201(Evidence code:IEA/Database source:InterPro:IPR033076)Q29RU4(Evidence code:IEA/Database source:InterPro:IPR001862), B2M C9 C7 CD36 C6,BP,5,5 of 214,4.95,2.34,0.0007609,0.004209
GO:0045071,negative regulation of viral genome replication,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens)O02853(Evidence code:IDA/Database source:), LTF PTGDS,BP,2,2 of 11,1.98,18.18,0.0007619,0.004209
GO:0006629,lipid metabolic process,P79345(Evidence code:IEA/Database source:UniProtKB-KW:KW-0443)P11151(Evidence code:IEA/Database source:InterPro:IPR002330|I)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0443)Q2UVX4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0443)P15497(Evidence code:IEA/Database source:UniProtKB-KW:KW-0443)P26779(Evidence code:IEA/Database source:InterPro:IPR007856), NPC2 LPL PTGDS C3 APOA1 PSAP,BP,6,6 of 325,5.94,1.85,0.0007834,0.004292
GO:0051496,positive regulation of stress fiber assembly,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens), APOA1 SERPINF2,BP,2,2 of 12,1.98,16.67,0.000887,0.004781
GO:0050832,defense response to fungus,P54228(Evidence code:IEA/Database source:UniProtKB-KW:KW-0295)Q8SPP7(Evidence code:IEA/Database source:UniProtKB-KW:KW-0295), CATHL6 PGLYRP1,BP,2,2 of 12,1.98,16.67,0.000887,0.004781
GO:0042470,melanosome,P05307(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P07688(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q95121(Evidence code:IEA/Database source:UniProtKB-SubCell:SL), P4HB CTSB SERPINF1,CC,3,3 of 56,2.97,5.36,0.0009109,0.00487
GO:0016324,apical plasma membrane,P26201(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q8WML4(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P02702(Evidence code:IEA/Database source:UniProtKB-SubCell:SL), CD36 MUC1 FOLR1,CC,3,3 of 60,2.97,5,0.001102,0.005845
GO:0030301,cholesterol transport,P79345(Evidence code:ISS/Database source:UniProtKB:P61916)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), NPC2 APOA1,BP,2,2 of 14,1.98,14.29,0.001165,0.006128
GO:0032760,positive regulation of tumor necrosis factor production,Q2TBI0(Evidence code:ISS/Database source:UniProtKB:P18428)Q95122(Evidence code:ISS/Database source:UniProtKB:P10810), LBP CD14,BP,2,2 of 15,1.98,13.33,0.001317,0.006822
GO:0005793,endoplasmic reticulum-Golgi intermediate compartment,Q0IIH5(Evidence code:IEA/Database source:UniProtKB:P80303|ens)Q0P569(Evidence code:IEA/Database source:UniProtKB:Q02818|ens), NUCB2 NUCB1,CC,2,2 of 15,1.98,13.33,0.001317,0.006822
GO:0007229,integrin-mediated signaling pathway,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)Q3T0Q4(Evidence code:ISS/Database source:UniProtKB:P22392), APOA1 NME2,BP,2,2 of 16,1.98,12.5,0.001479,0.007541
GO:0005044,scavenger receptor activity,Q32PI4(Evidence code:IEA/Database source:InterPro:IPR001190)F1N514(Evidence code:IEA/Database source:InterPro:IPR001190), CFI CD5L,MF,2,2 of 16,1.98,12.5,0.001479,0.007541
GO:0001938,positive regulation of endothelial cell proliferation,P30931(Evidence code:ISS/Database source:UniProtKB:P13726)Q2KIF2(Evidence code:IEA/Database source:UniProtKB:Q91XL1|ens), F3 LRG1,BP,2,2 of 17,1.98,11.76,0.001649,0.008346
GO:0042802,identical protein binding,P02754(Evidence code:IPI/Database source:UniProtKB:P02754)P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens)O46375(Evidence code:IEA/Database source:UniProtKB:P02766|ens)P80195(Evidence code:IPI/Database source:UniProtKB:P80195)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P00711(Evidence code:IPI/Database source:UniProtKB:P00711), LGB B2M TTR GLYCAM1 APOA1 LALBA,MF,6,6 of 379,5.94,1.58,0.001681,0.008444
GO:0016853,isomerase activity,P62935(Evidence code:IEA/Database source:UniProtKB-KW:KW-0413)P05307(Evidence code:IEA/Database source:InterPro:IPR005788)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0413), PPIA P4HB PTGDS,MF,3,3 of 75,2.97,4,0.002037,0.01015
GO:0004866,endopeptidase inhibitor activity,Q7SIH1(Evidence code:IEA/Database source:InterPro:IPR001599|I)Q2UVX4(Evidence code:IEA/Database source:InterPro:IPR001599|I)P12763(Evidence code:IBA/Database source:PANTHER:PTN000352258), A2M C3 AHSG,MF,3,3 of 76,2.97,3.95,0.002112,0.01045
GO:0030195,negative regulation of blood coagulation,P01045(Evidence code:IBA/Database source:PANTHER:PTN001790518)P01044(Evidence code:IBA/Database source:PANTHER:PTN001790518), KNG2 KNG1,BP,2,2 of 20,1.98,10,0.002213,0.01087
GO:0051897,positive regulation of protein kinase B signaling,P30922(Evidence code:ISS/Database source:UniProtKB:P36222)P30931(Evidence code:ISS/Database source:UniProtKB:P13726), CHI3L1 F3,BP,2,2 of 21,1.98,9.52,0.002419,0.01171
GO:0055072,iron ion homeostasis,P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0410)P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens), LTF B2M,BP,2,2 of 21,1.98,9.52,0.002419,0.01171
GO:0048471,perinuclear region of cytoplasm,P17697(Evidence code:ISS/Database source:UniProtKB:P10909)P30922(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)P07688(Evidence code:IEA/Database source:UniProtKB:P07858|ens)O02853(Evidence code:IEA/Database source:UniProtKB-SubCell:SL), CLU CHI3L1 CTSB PTGDS,CC,4,4 of 170,3.96,2.35,0.002469,0.01186
GO:0010469,regulation of signaling receptor activity,O46375(Evidence code:IEA/Database source:GO:0005179)P31096(Evidence code:IEA/Database source:GO:0005125), TTR SPP1,BP,2,2 of 22,1.98,9.09,0.002633,0.01256
GO:0071222,cellular response to lipopolysaccharide,Q2TBI0(Evidence code:ISS/Database source:UniProtKB:P18428)Q95122(Evidence code:ISS/Database source:UniProtKB:P10810), LBP CD14,BP,2,2 of 26,1.98,7.69,0.003576,0.0167
GO:2000117,negative regulation of cysteine-type endopeptidase activity,P02666(Evidence code:IEA/Database source:UniProtKB:P05814|ens)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens), CSN2 LTF,BP,2,2 of 26,1.98,7.69,0.003576,0.0167
GO:0009408,response to heat,P02666(Evidence code:IDA/Database source:)P06868(Evidence code:IDA/Database source:), CSN2 PLG,BP,2,2 of 26,1.98,7.69,0.003576,0.0167
GO:0005764,lysosome,P26779(Evidence code:IEA/Database source:InterPro:IPR008373|I)P07688(Evidence code:IEA/Database source:UniProtKB-KW:KW-0458)P79345(Evidence code:IEA/Database source:UniProtKB-KW:KW-0458), PSAP CTSB NPC2,CC,3,3 of 93,2.97,3.23,0.003664,0.01699
GO:0005543,phospholipid binding,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens)P30931(Evidence code:ISS/Database source:UniProtKB:P13726)Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006), APOA1 F3 APOE,MF,3,3 of 94,2.97,3.19,0.003771,0.01736
GO:0005829,cytosol,P80457(Evidence code:IBA/Database source:PANTHER:PTN000225632)P60712(Evidence code:TAS/Database source:)Q9XSG3(Evidence code:ISS/Database source:UniProtKB:O88844)P62935(Evidence code:ISS/Database source:UniProtKB:P62937)P17697(Evidence code:IEA/Database source:UniProtKB-SubCell:SL)Q3MHN2(Evidence code:IEA/Database source:UniProtKB:P02748|ens)P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens)A6H7B5(Evidence code:IEA/Database source:UniProtKB:Q9UNS2|ens), XDH ACTB IDH1 PPIA CLU C9 B2M COPS3,CC,8,8 of 769,7.92,1.04,0.004161,0.01903
GO:0045454,cell redox homeostasis,A6QQA8(Evidence code:IEA/Database source:InterPro:IPR013766)P05307(Evidence code:IEA/Database source:InterPro:IPR013766|I), QSOX1 P4HB,BP,2,2 of 30,1.98,6.67,0.004653,0.01929
GO:0051092,positive regulation of NF-kappaB transcription factor activity,P17697(Evidence code:ISS/Database source:UniProtKB:P10909)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens), CLU LTF,BP,2,2 of 35,1.98,5.71,0.006182,0.01929
GO:0008203,cholesterol metabolic process,P79345(Evidence code:IEA/Database source:UniProtKB-KW:KW-0153)P15497(Evidence code:IEA/Database source:UniProtKB-KW:KW-0153), NPC2 APOA1,BP,2,2 of 33,1.98,6.06,0.005546,0.01929
GO:0019838,growth factor binding,Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens)Q9MZ06(Evidence code:IEA/Database source:UniProtKB-KW:KW-0340), A2M FGFBP1,MF,2,2 of 29,1.98,6.9,0.004371,0.01929
GO:2000266,"regulation of blood coagulation, intrinsic pathway",P41361(Evidence code:IEA/Database source:InterPro:IPR015555),SERPINC1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:2000839,positive regulation of androstenedione secretion,P02662(Evidence code:IMP/Database source:),CSN1S1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0072378,"blood coagulation, fibrin clot formation",P00735(Evidence code:IEA/Database source:UniProtKB:P19221|ens),F2,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:1904434,positive regulation of ferrous iron binding,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0002034,regulation of blood vessel diameter by renin-angiotensin,P28800(Evidence code:IEA/Database source:UniProtKB:Q61247|ens),SERPINF2,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0004465,lipoprotein lipase activity,P11151(Evidence code:IEA/Database source:InterPro:IPR002330),LPL,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0033216,ferric iron import,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0002197,xanthine dehydrogenase complex,P80457(Evidence code:IDA/Database source:),XDH,CC,1,1 of 1,0.99,100,0.006284,0.01929
GO:0042158,lipoprotein biosynthetic process,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:1903720,negative regulation of I-kappaB phosphorylation,P02666(Evidence code:IDA/Database source:),CSN2,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:1904447,folate import across plasma membrane,P02702(Evidence code:IEA/Database source:InterPro:IPR032935),FOLR1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0070945,neutrophil mediated killing of gram-negative bacterium,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0033690,positive regulation of osteoblast proliferation,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0070326,very-low-density lipoprotein particle receptor binding,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0060054,positive regulation of epithelial cell proliferation involved in wound healing,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:1904437,positive regulation of transferrin receptor binding,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0008745,N-acetylmuramoyl-L-alanine amidase activity,Q8SPP7(Evidence code:IEA/Database source:InterPro:IPR002502|I),PGLYRP1,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:2000308,negative regulation of tumor necrosis factor (ligand) superfamily member 11 production,P24627(Evidence code:IDA/Database source:),LTF,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:1903456,"positive regulation of androst-4-ene-3,17-dione biosynthetic process",P02662(Evidence code:IMP/Database source:),CSN1S1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0002541,activation of plasma proteins involved in acute inflammatory response,P30931(Evidence code:ISS/Database source:UniProtKB:P13726),F3,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0002481,"antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent",P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0044117,growth of symbiont in host,Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O88593|ens),PGLYRP1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0004855,xanthine oxidase activity,P80457(Evidence code:IEA/Database source:InterPro:IPR014307),XDH,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0070051,fibrinogen binding,P00735(Evidence code:IPI/Database source:UniProtKB:P02671),F2,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0001869,"negative regulation of complement activation, lectin pathway",Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens),A2M,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0070543,response to linoleic acid,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0060354,negative regulation of cell adhesion molecule production,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0019836,hemolysis by symbiont of host erythrocytes,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0051659,maintenance of mitochondrion location,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0060770,negative regulation of epithelial cell proliferation involved in prostate gland development,Q95121(Evidence code:IEA/Database source:UniProtKB:P97298|ens),SERPINF1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0055096,low-density lipoprotein particle mediated signaling,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens),LPL,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0036393,thiocyanate peroxidase activity,P80025(Evidence code:IEA/Database source:InterPro:IPR029587),LPO,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:1903895,negative regulation of IRE1-mediated unfolded protein response,Q0VCX2(Evidence code:ISS/Database source:UniProtKB:G3I8R9),HSPA5,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0016019,peptidoglycan receptor activity,Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O75594|ens),PGLYRP1,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:1900390,regulation of iron ion import,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0031665,negative regulation of lipopolysaccharide-mediated signaling pathway,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0060736,prostate gland growth,P26779(Evidence code:IBA/Database source:PANTHER:PTN000159338),PSAP,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0019862,IgA binding,Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens),IGJ,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0009253,peptidoglycan catabolic process,Q8SPP7(Evidence code:IEA/Database source:InterPro:IPR002502|I),PGLYRP1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:1900221,regulation of amyloid-beta clearance,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0007016,cytoskeletal anchoring at plasma membrane,O18738(Evidence code:IEA/Database source:InterPro:IPR008465),DAG1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0090482,vitamin transmembrane transporter activity,Q3MHN5(Evidence code:IEA/Database source:InterPro:IPR000213),GC,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0030502,negative regulation of bone mineralization,P12763(Evidence code:ISS/Database source:UniProtKB:P29699),AHSG,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0004667,prostaglandin-D synthase activity,O02853(Evidence code:IEA/Database source:EC:5.3.99.2),PTGDS,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:2001245,regulation of phosphatidylcholine biosynthetic process,P10790(Evidence code:IEA/Database source:UniProtKB:P11404|ens),FABP3,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0019344,cysteine biosynthetic process,G3N2D8(Evidence code:IEA/Database source:UniProtKB:Q60928|ens),GGT1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:2000872,positive regulation of progesterone secretion,P02662(Evidence code:IMP/Database source:),CSN1S1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0060335,positive regulation of interferon-gamma-mediated signaling pathway,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0045499,chemorepellent activity,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0051673,membrane disruption in other organism,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0060332,positive regulation of response to interferon-gamma,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0030299,intestinal cholesterol absorption,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0032827,negative regulation of natural killer cell differentiation involved in immune response,Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O88593|ens),PGLYRP1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0051714,positive regulation of cytolysis in other organism,Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O75594|ens),PGLYRP1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0018401,peptidyl-proline hydroxylation to 4-hydroxy-L-proline,P05307(Evidence code:ISS/Database source:UniProtKB:P07237),P4HB,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0070053,thrombospondin receptor activity,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:1900159,positive regulation of bone mineralization involved in bone maturation,P24627(Evidence code:IDA/Database source:),LTF,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0071283,cellular response to iron(III) ion,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0031715,C5L2 anaphylatoxin chemotactic receptor binding,Q2UVX4(Evidence code:ISS/Database source:UniProtKB:P01024),C3,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:2000184,positive regulation of progesterone biosynthetic process,P02662(Evidence code:IMP/Database source:),CSN1S1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:1903589,positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,Q9MZ06(Evidence code:IEA/Database source:UniProtKB:Q14512|ens),FGFBP1,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0051838,cytolysis by host of symbiont cells,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0034191,apolipoprotein A-I receptor binding,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:1990712,HFE-transferrin receptor complex,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,CC,1,1 of 1,0.99,100,0.006284,0.01929
GO:0003094,glomerular filtration,Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens),IGJ,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0051787,misfolded protein binding,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,MF,1,1 of 1,0.99,100,0.006284,0.01929
GO:0032367,intracellular cholesterol transport,P79345(Evidence code:IEA/Database source:InterPro:IPR033916),NPC2,BP,1,1 of 1,0.99,100,0.006284,0.01929
GO:0006898,receptor-mediated endocytosis,F1N514(Evidence code:IEA/Database source:GO:0005044)Q32PI4(Evidence code:IEA/Database source:GO:0005044), CD5L CFI,BP,2,2 of 36,1.98,5.56,0.006511,0.01989
GO:0016323,basolateral plasma membrane,P80025(Evidence code:IEA/Database source:UniProtKB:P22079|ens)P08037(Evidence code:ISS/Database source:UniProtKB:P15291), LPO B4GALT1,CC,2,2 of 41,1.98,4.88,0.008276,0.02297
GO:0008360,regulation of cell shape,P07589(Evidence code:IEA/Database source:UniProtKB-KW:KW-0133)P00735(Evidence code:IEA/Database source:UniProtKB:P19221|ens), FN1 F2,BP,2,2 of 43,1.98,4.65,0.009035,0.02297
GO:0050880,regulation of blood vessel size,P01044(Evidence code:IEA/Database source:UniProtKB-KW:KW-0838)P01045(Evidence code:IEA/Database source:UniProtKB-KW:KW-0838), KNG1 KNG2,BP,2,2 of 43,1.98,4.65,0.009035,0.02297
GO:0006633,fatty acid biosynthetic process,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0275), LPL PTGDS,BP,2,2 of 44,1.98,4.55,0.009425,0.02297
GO:0007341,penetration of zona pellucida,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0001652,granular component,Q2KIS7(Evidence code:ISS/Database source:UniProtKB:P05452),CLEC3B,CC,1,1 of 2,0.99,50,0.009411,0.02297
GO:0071636,positive regulation of transforming growth factor beta production,P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens),SERPINF2,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0036374,glutathione hydrolase activity,G3N2D8(Evidence code:IEA/Database source:InterPro:IPR000101),GGT1,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0009115,xanthine catabolic process,P80457(Evidence code:ISS/Database source:UniProtKB:P22985),XDH,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0015884,folic acid transport,P02702(Evidence code:ISS/Database source:UniProtKB:P15328),FOLR1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:1900738,positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0035461,vitamin transmembrane transport,Q3MHN5(Evidence code:IEA/Database source:GO:0090482),GC,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0004854,xanthine dehydrogenase activity,P80457(Evidence code:IEA/Database source:InterPro:IPR014307),XDH,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0042125,protein galactosylation,P08037(Evidence code:IDA/Database source:),B4GALT1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0045187,"regulation of circadian sleep/wake cycle, sleep",O02853(Evidence code:ISS/Database source:UniProtKB:O09114),PTGDS,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0010641,positive regulation of platelet-derived growth factor receptor signaling pathway,P30931(Evidence code:ISS/Database source:UniProtKB:P13726),F3,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0060742,epithelial cell differentiation involved in prostate gland development,P26779(Evidence code:IBA/Database source:PANTHER:PTN000159338),PSAP,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0003831,"beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity",P08037(Evidence code:IEA/Database source:EC:2.4.1.38),B4GALT1,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0010756,positive regulation of plasminogen activation,Q2KIS7(Evidence code:ISS/Database source:UniProtKB:P43025),CLEC3B,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0043546,molybdopterin cofactor binding,P80457(Evidence code:IEA/Database source:InterPro:IPR022407),XDH,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0034185,apolipoprotein binding,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens),LPL,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0015232,heme transporter activity,Q3SZV7(Evidence code:IEA/Database source:InterPro:IPR016358),HPX,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0019959,interleukin-8 binding,Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens),A2M,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0032366,intracellular sterol transport,P79345(Evidence code:IEA/Database source:UniProtKB:P61916|ens),NPC2,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0090197,positive regulation of chemokine secretion,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens),LPL,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0070168,negative regulation of biomineral tissue development,P12763(Evidence code:IBA/Database source:PANTHER:PTN000352259),AHSG,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0090050,positive regulation of cell migration involved in sprouting angiogenesis,Q9MZ06(Evidence code:IEA/Database source:UniProtKB:Q14512|ens),FGFBP1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0034190,apolipoprotein receptor binding,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0004450,isocitrate dehydrogenase (NADP+) activity,Q9XSG3(Evidence code:IEA/Database source:InterPro:IPR004790),IDH1,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0016010,dystrophin-associated glycoprotein complex,O18738(Evidence code:IEA/Database source:InterPro:IPR008465),DAG1,CC,1,1 of 2,0.99,50,0.009411,0.02297
GO:0032489,regulation of Cdc42 protein signal transduction,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0071727,cellular response to triacyl bacterial lipopeptide,Q95122(Evidence code:ISS/Database source:UniProtKB:P08571),CD14,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0060058,positive regulation of apoptotic process involved in mammary gland involution,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0019966,interleukin-1 binding,Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens),A2M,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0019885,antigen processing and presentation of endogenous peptide antigen via MHC class I,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0030879,mammary gland development,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0005542,folic acid binding,P02702(Evidence code:IEA/Database source:InterPro:IPR032935),FOLR1,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:1902732,positive regulation of chondrocyte proliferation,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0000138,Golgi trans cisterna,P08037(Evidence code:ISS/Database source:UniProtKB:P15291),B4GALT1,CC,1,1 of 2,0.99,50,0.009411,0.02297
GO:2000255,negative regulation of male germ cell proliferation,O02853(Evidence code:IEA/Database source:UniProtKB:O09114|ens),PTGDS,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0015643,toxic substance binding,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:1990000,amyloid fibril formation,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0070327,thyroid hormone transport,O46375(Evidence code:IEA/Database source:InterPro:IPR030178),TTR,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0016018,cyclosporin A binding,P62935(Evidence code:ISS/Database source:UniProtKB:P62937),PPIA,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0044279,other organism membrane,Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-1053),C9,CC,1,1 of 2,0.99,50,0.009411,0.02297
GO:0034197,triglyceride transport,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0006097,glyoxylate cycle,Q9XSG3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0329),IDH1,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0015886,heme transport,Q3SZV7(Evidence code:IEA/Database source:InterPro:IPR016358),HPX,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:1900229,negative regulation of single-species biofilm formation in or on host organism,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0036143,kringle domain binding,Q2KIS7(Evidence code:IEA/Database source:UniProtKB:P05452|ens),CLEC3B,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0030492,hemoglobin binding,Q2TBU0(Evidence code:IEA/Database source:UniProtKB-KW:KW-0351),HP,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0004673,protein histidine kinase activity,Q3T0Q4(Evidence code:IEA/Database source:EC:2.7.13.3),NME2,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0071281,cellular response to iron ion,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0003945,N-acetyllactosamine synthase activity,P08037(Evidence code:IEA/Database source:EC:2.4.1.90),B4GALT1,MF,1,1 of 2,0.99,50,0.009411,0.02297
GO:0048712,negative regulation of astrocyte differentiation,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 2,0.99,50,0.009411,0.02297
GO:0016045,detection of bacterium,Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O75594|ens),PGLYRP1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0042581,specific granule,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,CC,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0043120,tumor necrosis factor binding,Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens),A2M,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0002227,innate immune response in mucosa,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0070653,high-density lipoprotein particle receptor binding,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0051788,response to misfolded protein,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0010903,negative regulation of very-low-density lipoprotein particle remodeling,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:2000060,positive regulation of ubiquitin-dependent protein catabolic process,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0031545,peptidyl-proline 4-dioxygenase activity,P05307(Evidence code:IBA/Database source:PANTHER:PTN001053176),P4HB,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:1900121,negative regulation of receptor binding,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0072606,interleukin-8 secretion,P30922(Evidence code:ISS/Database source:UniProtKB:Q61362),CHI3L1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:1900122,positive regulation of receptor binding,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0002281,macrophage activation involved in immune response,Q2TBI0(Evidence code:ISS/Database source:UniProtKB:P18428),LBP,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0051918,negative regulation of fibrinolysis,P28800(Evidence code:IEA/Database source:InterPro:IPR033833),SERPINF2,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0030970,"retrograde protein transport, ER to cytosol",Q3MHX6(Evidence code:IBA/Database source:PANTHER:PTN000395729),OS9,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0070324,thyroid hormone binding,O46375(Evidence code:IEA/Database source:InterPro:IPR030178),TTR,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0006102,isocitrate metabolic process,Q9XSG3(Evidence code:IEA/Database source:InterPro:IPR004790),IDH1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0004656,procollagen-proline 4-dioxygenase activity,P05307(Evidence code:ISS/Database source:UniProtKB:P07237),P4HB,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0010757,negative regulation of plasminogen activation,P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens),SERPINF2,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0065010,extracellular membrane-bounded organelle,P12763(Evidence code:IDA/Database source:),AHSG,CC,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:1900227,positive regulation of NLRP3 inflammasome complex assembly,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0006656,phosphatidylcholine biosynthetic process,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0004322,ferroxidase activity,Q32P72(Evidence code:IEA/Database source:InterPro:IPR027150),CP,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0034363,intermediate-density lipoprotein particle,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,CC,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0019870,potassium channel inhibitor activity,P02666(Evidence code:IDA/Database source:),CSN2,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0050713,negative regulation of interleukin-1 beta secretion,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0051000,positive regulation of nitric-oxide synthase activity,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0034145,positive regulation of toll-like receptor 4 signaling pathway,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0006621,protein retention in ER lumen,Q3MHX6(Evidence code:ISS/Database source:UniProtKB:Q13438),OS9,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0030151,molybdenum ion binding,P80457(Evidence code:IDA/Database source:),XDH,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0001533,cornified envelope,G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04264|ens),KRT1,CC,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0006825,copper ion transport,Q32P72(Evidence code:IEA/Database source:InterPro:IPR027150),CP,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0046696,lipopolysaccharide receptor complex,Q95122(Evidence code:ISS/Database source:UniProtKB:P08571),CD14,CC,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:1905286,serine-type peptidase complex,P30931(Evidence code:IEA/Database source:UniProtKB:P13726|ens),F3,CC,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0045780,positive regulation of bone resorption,P31096(Evidence code:IBA/Database source:PANTHER:PTN001635232),SPP1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0006751,glutathione catabolic process,G3N2D8(Evidence code:IEA/Database source:InterPro:IPR000101),GGT1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0008035,high-density lipoprotein particle binding,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0018206,peptidyl-methionine modification,P15497(Evidence code:ISS/Database source:UniProtKB:P02647),APOA1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0005499,vitamin D binding,Q3MHN5(Evidence code:IEA/Database source:InterPro:IPR000213),GC,MF,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0042159,lipoprotein catabolic process,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0019732,antifungal humoral response,P24627(Evidence code:IEA/Database source:InterPro:IPR030684),LTF,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0007250,activation of NF-kappaB-inducing kinase activity,P30922(Evidence code:ISS/Database source:UniProtKB:Q61362),CHI3L1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0030325,adrenal gland development,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:2001205,negative regulation of osteoclast development,P24627(Evidence code:IDA/Database source:),LTF,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0002925,positive regulation of humoral immune response mediated by circulating immunoglobulin,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0010886,positive regulation of cholesterol storage,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens),LPL,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0006707,cholesterol catabolic process,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,BP,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0035267,NuA4 histone acetyltransferase complex,P60712(Evidence code:ISS/Database source:UniProtKB:P60709),ACTB,CC,1,1 of 3,0.99,33.33,0.01253,0.02596
GO:0005634,nucleus,A6H7B5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0539)Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0539)Q8WML4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0539)O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0539)O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0539)P62935(Evidence code:ISS/Database source:UniProtKB:P62937)Q0IIH5(Evidence code:IEA/Database source:UniProtKB:P81117|ens)P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0539)P60712(Evidence code:ISS/Database source:UniProtKB:P60709), COPS3 NME2 MUC1 PTGDS DAG1 PPIA NUCB2 CLU ACTB,CC,9,9 of 1172,8.91,0.77,0.01563,0.03013
GO:0005506,iron ion binding,P24627(Evidence code:IEA/Database source:InterPro:IPR030684)P80457(Evidence code:IEA/Database source:InterPro:IPR016208), LTF XDH,MF,2,2 of 57,1.98,3.51,0.01516,0.03013
GO:0032463,negative regulation of protein homooligomerization,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0050919,negative chemotaxis,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0097433,dense body,P60712(Evidence code:ISS/Database source:UniProtKB:P60706),ACTB,CC,1,1 of 4,0.99,25,0.01564,0.03013
GO:0019432,triglyceride biosynthetic process,P11151(Evidence code:ISS/Database source:UniProtKB:P06858),LPL,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0002740,negative regulation of cytokine secretion involved in immune response,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:1903488,negative regulation of lactation,P02666(Evidence code:IDA/Database source:),CSN2,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0000338,protein deneddylation,A6H7B5(Evidence code:IEA/Database source:UniProtKB:Q9UNS2|ens),COPS3,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0010744,positive regulation of macrophage derived foam cell differentiation,P11151(Evidence code:IEA/Database source:UniProtKB:P11152|ens),LPL,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0006032,chitin catabolic process,P30922(Evidence code:IBA/Database source:PANTHER:PTN000126614),CHI3L1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0043534,blood vessel endothelial cell migration,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0045136,development of secondary sexual characteristics,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:1900016,negative regulation of cytokine production involved in inflammatory response,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0042612,MHC class I protein complex,P01888(Evidence code:IEA/Database source:InterPro:IPR015707),B2M,CC,1,1 of 4,0.99,25,0.01564,0.03013
GO:0035437,maintenance of protein localization in endoplasmic reticulum,Q0VCX2(Evidence code:ISS/Database source:UniProtKB:P11021),HSPA5,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0034375,high-density lipoprotein particle remodeling,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0018158,protein oxidation,P15497(Evidence code:ISS/Database source:UniProtKB:P02647),APOA1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0006228,UTP biosynthetic process,Q3T0Q4(Evidence code:IEA/Database source:InterPro:IPR001564),NME2,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0004568,chitinase activity,P30922(Evidence code:IBA/Database source:PANTHER:PTN000126614),CHI3L1,MF,1,1 of 4,0.99,25,0.01564,0.03013
GO:0033077,T cell differentiation in thymus,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0060055,angiogenesis involved in wound healing,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0034115,negative regulation of heterotypic cell-cell adhesion,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0090218,positive regulation of lipid kinase activity,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 4,0.99,25,0.01564,0.03013
GO:0008202,steroid metabolic process,P15497(Evidence code:IEA/Database source:UniProtKB-KW:KW-0753)P79345(Evidence code:IEA/Database source:UniProtKB-KW:KW-0753), APOA1 NPC2,BP,2,2 of 59,1.98,3.39,0.01615,0.03103
GO:0005856,cytoskeleton,O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0206)Q3SX14(Evidence code:IEA/Database source:UniProtKB-KW:KW-0206)P60712(Evidence code:ISS/Database source:UniProtKB:P60706), DAG1 GSN ACTB,CC,3,3 of 165,2.97,1.82,0.01678,0.03215
GO:0046718,viral entry into host cell,P07688(Evidence code:IEA/Database source:UniProtKB:P10605|ens),CTSB,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0060349,bone morphogenesis,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0046697,decidualization,P07688(Evidence code:IEA/Database source:UniProtKB:P10605|ens),CTSB,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0006012,galactose metabolic process,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0032780,negative regulation of ATPase activity,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0051290,protein heterotetramerization,G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04264|ens),KRT1,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0035375,zymogen binding,P02663(Evidence code:IPI/Database source:UniProtKB:P00750),CSN1S2,MF,1,1 of 5,0.99,20,0.01873,0.03384
GO:0042744,hydrogen peroxide catabolic process,P80025(Evidence code:IEA/Database source:UniProtKB-KW:KW-0376),LPO,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0050702,interleukin-1 beta secretion,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0043236,laminin binding,O18738(Evidence code:IDA/Database source:),DAG1,MF,1,1 of 5,0.99,20,0.01873,0.03384
GO:0035250,UDP-galactosyltransferase activity,P08037(Evidence code:ISS/Database source:UniProtKB:P15291),B4GALT1,MF,1,1 of 5,0.99,20,0.01873,0.03384
GO:0097067,cellular response to thyroid hormone stimulus,P07688(Evidence code:IEA/Database source:UniProtKB:P07858|ens),CTSB,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0006750,glutathione biosynthetic process,G3N2D8(Evidence code:IEA/Database source:UniProtKB:Q60928|ens),GGT1,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0010890,positive regulation of sequestering of triglyceride,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens),LPL,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0000413,protein peptidyl-prolyl isomerization,P62935(Evidence code:IEA/Database source:InterPro:IPR002130),PPIA,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0043394,proteoglycan binding,P07688(Evidence code:IEA/Database source:UniProtKB:P07858|ens),CTSB,MF,1,1 of 5,0.99,20,0.01873,0.03384
GO:0051014,actin filament severing,Q3SX14(Evidence code:IEA/Database source:InterPro:IPR030004),GSN,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0071813,lipoprotein particle binding,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,MF,1,1 of 5,0.99,20,0.01873,0.03384
GO:0008061,chitin binding,P30922(Evidence code:IEA/Database source:InterPro:IPR011583|I),CHI3L1,MF,1,1 of 5,0.99,20,0.01873,0.03384
GO:0097009,energy homeostasis,P26201(Evidence code:ISS/Database source:UniProtKB:Q07969),CD36,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0008211,glucocorticoid metabolic process,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 5,0.99,20,0.01873,0.03384
GO:0050727,regulation of inflammatory response,G3N2D8(Evidence code:IEA/Database source:UniProtKB:Q60928|ens)P12763(Evidence code:ISS/Database source:UniProtKB:P02765), GGT1 AHSG,BP,2,2 of 66,1.98,3.03,0.0198,0.03568
GO:0009312,oligosaccharide biosynthetic process,P08037(Evidence code:ISS/Database source:UniProtKB:P15291),B4GALT1,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0030511,positive regulation of transforming growth factor beta receptor signaling pathway,Q2KIF2(Evidence code:IEA/Database source:UniProtKB:Q91XL1|ens),LRG1,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0071404,cellular response to low-density lipoprotein particle stimulus,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0070741,response to interleukin-6,P30922(Evidence code:ISS/Database source:UniProtKB:P36222),CHI3L1,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0006183,GTP biosynthetic process,Q3T0Q4(Evidence code:IEA/Database source:InterPro:IPR001564),NME2,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0034142,toll-like receptor 4 signaling pathway,Q95122(Evidence code:ISS/Database source:UniProtKB:P10810),CD14,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0006241,CTP biosynthetic process,Q3T0Q4(Evidence code:IEA/Database source:InterPro:IPR001564),NME2,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0051016,barbed-end actin filament capping,Q3SX14(Evidence code:IEA/Database source:InterPro:IPR030004),GSN,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:1902175,regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,P05307(Evidence code:IBA/Database source:PANTHER:PTN001053176),P4HB,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0005640,nuclear outer membrane,Q0IIH5(Evidence code:IEA/Database source:UniProtKB:P81117|ens),NUCB2,CC,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0032461,positive regulation of protein oligomerization,Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens),IGJ,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:1902230,negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0046320,regulation of fatty acid oxidation,P10790(Evidence code:IEA/Database source:UniProtKB:P11404|ens),FABP3,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0001916,positive regulation of T cell mediated cytotoxicity,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0042572,retinol metabolic process,O46375(Evidence code:IEA/Database source:InterPro:IPR030178),TTR,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0020027,hemoglobin metabolic process,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0006103,2-oxoglutarate metabolic process,Q9XSG3(Evidence code:ISS/Database source:UniProtKB:O75874),IDH1,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0032689,negative regulation of interferon-gamma production,Q8SPP7(Evidence code:IEA/Database source:UniProtKB:O88593|ens),PGLYRP1,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0061436,establishment of skin barrier,G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04104|ens),KRT1,BP,1,1 of 6,0.99,16.67,0.02182,0.03738
GO:0034976,response to endoplasmic reticulum stress,P05307(Evidence code:IBA/Database source:PANTHER:PTN000432607)Q3MHX6(Evidence code:ISS/Database source:UniProtKB:Q13438), P4HB OS9,BP,2,2 of 70,1.98,2.86,0.02204,0.03765
GO:0001525,angiogenesis,P07589(Evidence code:IEA/Database source:UniProtKB-KW:KW-0037)Q95114(Evidence code:IEA/Database source:UniProtKB-KW:KW-0037), FN1 MFGE8,BP,2,2 of 71,1.98,2.82,0.02261,0.03844
GO:0045121,membrane raft,P26201(Evidence code:ISS/Database source:UniProtKB:P16671)Q95122(Evidence code:ISS/Database source:UniProtKB:P08571), CD36 CD14,CC,2,2 of 71,1.98,2.82,0.02261,0.03844
GO:0043066,negative regulation of apoptotic process,P24627(Evidence code:IDA/Database source:)P02662(Evidence code:IMP/Database source:)P02769(Evidence code:ISS/Database source:UniProtKB:P02768), LTF CSN1S1 ALB,BP,3,3 of 186,2.97,1.61,0.02278,0.03863
GO:0002474,antigen processing and presentation of peptide antigen via MHC class I,P01888(Evidence code:IEA/Database source:UniProtKB-KW:KW-0490),B2M,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0060046,regulation of acrosome reaction,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0009101,glycoprotein biosynthetic process,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0030194,positive regulation of blood coagulation,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0010800,positive regulation of peptidyl-threonine phosphorylation,P30922(Evidence code:ISS/Database source:UniProtKB:Q61362),CHI3L1,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:1900026,positive regulation of substrate adhesion-dependent cell spreading,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0050766,positive regulation of phagocytosis,P12763(Evidence code:ISS/Database source:UniProtKB:P02765),AHSG,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0036041,long-chain fatty acid binding,P02754(Evidence code:IDA/Database source:),LGB,MF,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0004806,triglyceride lipase activity,P11151(Evidence code:IEA/Database source:UniProtKB:P06858|ens),LPL,MF,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0042060,wound healing,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0050892,intestinal absorption,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0050750,low-density lipoprotein particle receptor binding,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,MF,1,1 of 7,0.99,14.29,0.0249,0.04096
GO:0018149,peptide cross-linking,G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04264|ens),KRT1,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0001935,endothelial cell proliferation,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0003756,protein disulfide isomerase activity,P05307(Evidence code:IEA/Database source:InterPro:IPR005792),P4HB,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0006826,iron ion transport,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0019825,oxygen binding,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0004550,nucleoside diphosphate kinase activity,Q3T0Q4(Evidence code:IEA/Database source:InterPro:IPR001564),NME2,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0002726,positive regulation of T cell cytokine production,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0043539,protein serine/threonine kinase activator activity,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0030574,collagen catabolic process,P07688(Evidence code:IEA/Database source:UniProtKB:P07858|ens),CTSB,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0030282,bone mineralization,Q2KIS7(Evidence code:IEA/Database source:UniProtKB:P05452|ens),CLEC3B,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0008191,metalloendopeptidase inhibitor activity,P02666(Evidence code:IEA/Database source:UniProtKB-KW:KW-0483),CSN2,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0008378,galactosyltransferase activity,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0043014,alpha-tubulin binding,P08037(Evidence code:ISS/Database source:UniProtKB:P15291-1),B4GALT1,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0010866,regulation of triglyceride biosynthetic process,Q2UVX4(Evidence code:ISS/Database source:UniProtKB:P01024),C3,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0050909,sensory perception of taste,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0019841,retinol binding,P02754(Evidence code:IEA/Database source:UniProtKB-KW:KW-0683),LGB,MF,1,1 of 8,0.99,12.5,0.02797,0.04425
GO:0016491,oxidoreductase activity,P80457(Evidence code:IEA/Database source:InterPro:IPR002346|I)P80025(Evidence code:IEA/Database source:UniProtKB-KW:KW-0560)A6QQA8(Evidence code:IEA/Database source:UniProtKB-KW:KW-0560)Q9XSG3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0560), XDH LPO QSOX1 IDH1,MF,4,4 of 361,3.96,1.11,0.03008,0.04748
GO:0010884,positive regulation of lipid storage,Q2UVX4(Evidence code:ISS/Database source:UniProtKB:P01024),C3,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0030516,regulation of axon extension,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0007595,lactation,P02666(Evidence code:IEA/Database source:UniProtKB:P05814|ens),CSN2,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0060761,negative regulation of response to cytokine stimulus,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0010828,positive regulation of glucose transmembrane transport,Q2UVX4(Evidence code:ISS/Database source:UniProtKB:P01024),C3,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0048514,blood vessel morphogenesis,P28800(Evidence code:IEA/Database source:UniProtKB:Q61247|ens),SERPINF2,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0042026,protein refolding,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0007193,adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,P26779(Evidence code:IBA/Database source:PANTHER:PTN000159338),PSAP,BP,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0048487,beta-tubulin binding,P08037(Evidence code:ISS/Database source:UniProtKB:P15291-1),B4GALT1,MF,1,1 of 9,0.99,11.11,0.03102,0.04795
GO:0006979,response to oxidative stress,Q9XSG3(Evidence code:ISS/Database source:UniProtKB:O88844)P80025(Evidence code:IEA/Database source:InterPro:IPR010255), IDH1 LPO,BP,2,2 of 86,1.98,2.33,0.03192,0.0491
GO:0006631,fatty acid metabolic process,O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0276)Q2UVX4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0276), PTGDS C3,BP,2,2 of 86,1.98,2.33,0.03192,0.0491
GO:0051260,protein homooligomerization,P08037(Evidence code:IEA/Database source:UniProtKB:P15291|ens)Q3MHN2(Evidence code:ISS/Database source:UniProtKB:P02748), B4GALT1 C9,BP,2,2 of 88,1.98,2.27,0.03325,0.05103
GO:0045745,positive regulation of G-protein coupled receptor protein signaling pathway,Q2UVX4(Evidence code:ISS/Database source:UniProtKB:P01024),C3,BP,1,1 of 10,0.99,10,0.03407,0.05169
GO:0035025,positive regulation of Rho protein signal transduction,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 10,0.99,10,0.03407,0.05169
GO:0048661,positive regulation of smooth muscle cell proliferation,P28800(Evidence code:IEA/Database source:UniProtKB:Q61247|ens),SERPINF2,BP,1,1 of 10,0.99,10,0.03407,0.05169
GO:0030057,desmosome,P08037(Evidence code:ISS/Database source:UniProtKB:P15291),B4GALT1,CC,1,1 of 10,0.99,10,0.03407,0.05169
GO:0045669,positive regulation of osteoblast differentiation,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,BP,1,1 of 10,0.99,10,0.03407,0.05169
GO:0006644,phospholipid metabolic process,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens)P11151(Evidence code:IDA/Database source:), APOA1 LPL,BP,2,2 of 91,1.98,2.2,0.0353,0.05343
GO:0005791,rough endoplasmic reticulum,O02853(Evidence code:ISS/Database source:UniProtKB:P41222),PTGDS,CC,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0070542,response to fatty acid,P26201(Evidence code:ISS/Database source:UniProtKB:Q07969),CD36,BP,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0071560,cellular response to transforming growth factor beta stimulus,Q2KIS7(Evidence code:IEA/Database source:UniProtKB:P05452|ens),CLEC3B,BP,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0007339,binding of sperm to zona pellucida,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0030324,lung development,P30922(Evidence code:ISS/Database source:UniProtKB:P36222),CHI3L1,BP,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0071944,cell periphery,Q3T0Q4(Evidence code:ISS/Database source:UniProtKB:P22392),NME2,CC,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0008180,COP9 signalosome,A6H7B5(Evidence code:IEA/Database source:InterPro:IPR037753),COPS3,CC,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0019915,lipid storage,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0050873,brown fat cell differentiation,Q2KIF2(Evidence code:IEA/Database source:UniProtKB:Q91XL1|ens),LRG1,BP,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0071949,FAD binding,P80457(Evidence code:IEA/Database source:InterPro:IPR016166),XDH,MF,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0042583,chromaffin granule,P17697(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),CLU,CC,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0031663,lipopolysaccharide-mediated signaling pathway,Q95122(Evidence code:ISS/Database source:UniProtKB:P10810),CD14,BP,1,1 of 11,0.99,9.09,0.03711,0.05468
GO:0016021,integral component of membrane,P26201(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812)Q3MHN2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812)P30931(Evidence code:IEA/Database source:InterPro:IPR001187)G3N2D8(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812)Q8WML4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812)P81265(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812)P08037(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812)O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812)P18892(Evidence code:IEA/Database source:UniProtKB-KW:KW-0812), CD36 C9 F3 GGT1 MUC1 PIGR B4GALT1 DAG1 BTN1A1,CC,9,9 of 1299,8.91,0.69,0.04021,0.05808
GO:0006457,protein folding,P62935(Evidence code:IEA/Database source:InterPro:IPR020892)P05307(Evidence code:IBA/Database source:PANTHER:PTN000432607), PPIA P4HB,BP,2,2 of 97,1.98,2.06,0.03953,0.05808
GO:0006144,purine nucleobase metabolic process,O46375(Evidence code:IBA/Database source:PANTHER:PTN000044593),TTR,BP,1,1 of 12,0.99,8.33,0.04014,0.05808
GO:0051281,positive regulation of release of sequestered calcium ion into cytosol,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 12,0.99,8.33,0.04014,0.05808
GO:0051693,actin filament capping,Q3SX14(Evidence code:IEA/Database source:UniProtKB-KW:KW-0117),GSN,BP,1,1 of 12,0.99,8.33,0.04014,0.05808
GO:0050840,extracellular matrix binding,P31096(Evidence code:IBA/Database source:PANTHER:PTN001635232),SPP1,MF,1,1 of 12,0.99,8.33,0.04014,0.05808
GO:0045646,regulation of erythrocyte differentiation,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 12,0.99,8.33,0.04014,0.05808
GO:0043124,negative regulation of I-kappaB kinase/NF-kappaB signaling,P02666(Evidence code:IDA/Database source:),CSN2,BP,1,1 of 12,0.99,8.33,0.04014,0.05808
GO:0042168,heme metabolic process,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 12,0.99,8.33,0.04014,0.05808
GO:0045010,actin nucleation,Q3SX14(Evidence code:IEA/Database source:InterPro:IPR030004),GSN,BP,1,1 of 13,0.99,7.69,0.04316,0.0614
GO:0001516,prostaglandin biosynthetic process,O02853(Evidence code:ISS/Database source:UniProtKB:O09114),PTGDS,BP,1,1 of 13,0.99,7.69,0.04316,0.0614
GO:0048260,positive regulation of receptor-mediated endocytosis,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 13,0.99,7.69,0.04316,0.0614
GO:0032374,regulation of cholesterol transport,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006),APOE,BP,1,1 of 13,0.99,7.69,0.04316,0.0614
GO:0005501,retinoid binding,O02853(Evidence code:ISS/Database source:UniProtKB:O09114),PTGDS,MF,1,1 of 13,0.99,7.69,0.04316,0.0614
GO:0006919,activation of cysteine-type endopeptidase activity involved in apoptotic process,P30931(Evidence code:ISS/Database source:UniProtKB:P13726),F3,BP,1,1 of 13,0.99,7.69,0.04316,0.0614
GO:0030199,collagen fibril organization,P28800(Evidence code:IEA/Database source:UniProtKB:Q61247|ens),SERPINF2,BP,1,1 of 13,0.99,7.69,0.04316,0.0614
GO:0005925,focal adhesion,Q3T0Q4(Evidence code:ISS/Database source:UniProtKB:P22392)P60712(Evidence code:ISS/Database source:UniProtKB:P60706), NME2 ACTB,CC,2,2 of 103,1.98,1.94,0.04394,0.06225
GO:0046982,protein heterodimerization activity,G3N0V2(Evidence code:IEA/Database source:UniProtKB:P04264|ens)P05307(Evidence code:ISS/Database source:UniProtKB:P07237), KRT1 P4HB,MF,2,2 of 103,1.98,1.94,0.04394,0.06225
GO:0009749,response to glucose,P11151(Evidence code:IDA/Database source:),LPL,BP,1,1 of 14,0.99,7.14,0.04617,0.06527
GO:0097718,disordered domain specific binding,P07589(Evidence code:IPI/Database source:UniProtKB:Q06556),FN1,MF,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0048306,calcium-dependent protein binding,Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens),A2M,MF,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0048863,stem cell differentiation,Q7SIH1(Evidence code:IEA/Database source:UniProtKB:Q6GQT1|ens),A2M,BP,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0030145,manganese ion binding,P08037(Evidence code:ISS/Database source:UniProtKB:P15291),B4GALT1,MF,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0005160,transforming growth factor beta receptor binding,Q2KIF2(Evidence code:IEA/Database source:UniProtKB:Q91XL1|ens),LRG1,MF,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0002639,positive regulation of immunoglobulin production,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0005518,collagen binding,P07688(Evidence code:IEA/Database source:UniProtKB:P07858|ens),CTSB,MF,1,1 of 15,0.99,6.67,0.04917,0.06834
GO:0016887,ATPase activity,P17697(Evidence code:ISS/Database source:UniProtKB:P10909)Q0VCX2(Evidence code:ISS/Database source:UniProtKB:G3I8R9), CLU HSPA5,MF,2,2 of 110,1.98,1.82,0.0493,0.06838
GO:0008047,enzyme activator activity,P26779(Evidence code:IBA/Database source:PANTHER:PTN001352635)P00735(Evidence code:IEA/Database source:UniProtKB:P19221|ens), PSAP F2,MF,2,2 of 113,1.98,1.77,0.05167,0.07116
GO:0030500,regulation of bone mineralization,P12763(Evidence code:IEA/Database source:UniProtKB-KW:KW-0495),AHSG,BP,1,1 of 16,0.99,6.25,0.05216,0.07116
GO:0032729,positive regulation of interferon-gamma production,Q95122(Evidence code:ISS/Database source:UniProtKB:P10810),CD14,BP,1,1 of 16,0.99,6.25,0.05216,0.07116
GO:0003796,lysozyme activity,P00711(Evidence code:IBA/Database source:PANTHER:PTN001685978),LALBA,MF,1,1 of 16,0.99,6.25,0.05216,0.07116
GO:0051537,"2 iron, 2 sulfur cluster binding",P80457(Evidence code:IEA/Database source:InterPro:IPR006058),XDH,MF,1,1 of 16,0.99,6.25,0.05216,0.07116
GO:0046330,positive regulation of JNK cascade,P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens),SERPINF2,BP,1,1 of 16,0.99,6.25,0.05216,0.07116
GO:0016998,cell wall macromolecule catabolic process,P00711(Evidence code:IBA/Database source:PANTHER:PTN001685978),LALBA,BP,1,1 of 16,0.99,6.25,0.05216,0.07116
GO:0005504,fatty acid binding,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,MF,1,1 of 16,0.99,6.25,0.05216,0.07116
GO:0002526,acute inflammatory response,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 17,0.99,5.88,0.05514,0.07461
GO:0006693,prostaglandin metabolic process,O02853(Evidence code:IEA/Database source:UniProtKB-KW:KW-0644),PTGDS,BP,1,1 of 17,0.99,5.88,0.05514,0.07461
GO:0001906,cell killing,Q3MHN2(Evidence code:ISS/Database source:UniProtKB:P02748),C9,BP,1,1 of 17,0.99,5.88,0.05514,0.07461
GO:0045095,keratin filament,G3N0V2(Evidence code:IEA/Database source:InterPro:IPR003054),KRT1,CC,1,1 of 17,0.99,5.88,0.05514,0.07461
GO:0043065,positive regulation of apoptotic process,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens)P17697(Evidence code:ISS/Database source:UniProtKB:P10909-4), B4GALT1 CLU,BP,2,2 of 121,1.98,1.65,0.05817,0.0776
GO:0032436,positive regulation of proteasomal ubiquitin-dependent protein catabolic process,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,BP,1,1 of 18,0.99,5.56,0.05811,0.0776
GO:0004896,cytokine receptor activity,P30931(Evidence code:IBA/Database source:PANTHER:PTN000466212),F3,MF,1,1 of 18,0.99,5.56,0.05811,0.0776
GO:0006641,triglyceride metabolic process,P11151(Evidence code:IDA/Database source:),LPL,BP,1,1 of 18,0.99,5.56,0.05811,0.0776
GO:0014068,positive regulation of phosphatidylinositol 3-kinase signaling,P00735(Evidence code:IEA/Database source:UniProtKB:P19221|ens),F2,BP,1,1 of 18,0.99,5.56,0.05811,0.0776
GO:0030136,clathrin-coated vesicle,P02702(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),FOLR1,CC,1,1 of 18,0.99,5.56,0.05811,0.0776
GO:0031623,receptor internalization,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 18,0.99,5.56,0.05811,0.0776
GO:0006511,ubiquitin-dependent protein catabolic process,Q3MHX6(Evidence code:ISS/Database source:UniProtKB:Q13438)A6H7B5(Evidence code:IBA/Database source:PANTHER:PTN000079485), OS9 COPS3,BP,2,2 of 122,1.98,1.64,0.059,0.07855
GO:0003779,actin binding,Q3MHN5(Evidence code:IEA/Database source:UniProtKB-KW:KW-0009)Q3SX14(Evidence code:IEA/Database source:UniProtKB-KW:KW-0009), GC GSN,MF,2,2 of 124,1.98,1.61,0.06068,0.08034
GO:2001244,positive regulation of intrinsic apoptotic signaling pathway,P17697(Evidence code:ISS/Database source:UniProtKB:P10909-4),CLU,BP,1,1 of 19,0.99,5.26,0.06108,0.08034
GO:0004601,peroxidase activity,P80025(Evidence code:IEA/Database source:InterPro:IPR010255),LPO,MF,1,1 of 19,0.99,5.26,0.06108,0.08034
GO:0002221,pattern recognition receptor signaling pathway,Q8SPP7(Evidence code:IEA/Database source:GO:0016019),PGLYRP1,BP,1,1 of 19,0.99,5.26,0.06108,0.08034
GO:0048771,tissue remodeling,P06868(Evidence code:IEA/Database source:UniProtKB-KW:KW-0797),PLG,BP,1,1 of 19,0.99,5.26,0.06108,0.08034
GO:0001726,ruffle,Q3T0Q4(Evidence code:ISS/Database source:UniProtKB:P22392),NME2,CC,1,1 of 19,0.99,5.26,0.06108,0.08034
GO:0005811,lipid droplet,Q9TUM6(Evidence code:IEA/Database source:UniProtKB-KW:KW-0551),PLIN2,CC,1,1 of 20,0.99,5,0.06403,0.0834
GO:0007338,single fertilization,Q95114(Evidence code:IEA/Database source:UniProtKB-KW:KW-0278),MFGE8,BP,1,1 of 20,0.99,5,0.06403,0.0834
GO:0010977,negative regulation of neuron projection development,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 20,0.99,5,0.06403,0.0834
GO:2000379,positive regulation of reactive oxygen species metabolic process,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 20,0.99,5,0.06403,0.0834
GO:0030175,filopodium,P08037(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),B4GALT1,CC,1,1 of 20,0.99,5,0.06403,0.0834
GO:0006165,nucleoside diphosphate phosphorylation,Q3T0Q4(Evidence code:IEA/Database source:InterPro:IPR001564),NME2,BP,1,1 of 21,0.99,4.76,0.06697,0.08622
GO:0048754,branching morphogenesis of an epithelial tube,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 21,0.99,4.76,0.06697,0.08622
GO:0048525,negative regulation of viral process,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,BP,1,1 of 21,0.99,4.76,0.06697,0.08622
GO:0032092,positive regulation of protein binding,P01888(Evidence code:IEA/Database source:UniProtKB:P61769|ens),B2M,BP,1,1 of 21,0.99,4.76,0.06697,0.08622
GO:0009611,response to wounding,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 21,0.99,4.76,0.06697,0.08622
GO:0030433,ubiquitin-dependent ERAD pathway,Q3MHX6(Evidence code:ISS/Database source:UniProtKB:Q13438),OS9,BP,1,1 of 21,0.99,4.76,0.06697,0.08622
GO:0002064,epithelial cell development,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 22,0.99,4.55,0.06991,0.08913
GO:0071356,cellular response to tumor necrosis factor,P30922(Evidence code:ISS/Database source:UniProtKB:Q9WTV1),CHI3L1,BP,1,1 of 22,0.99,4.55,0.06991,0.08913
GO:0006487,protein N-linked glycosylation,P08037(Evidence code:ISS/Database source:UniProtKB:P15291),B4GALT1,BP,1,1 of 22,0.99,4.55,0.06991,0.08913
GO:0032580,Golgi cisterna membrane,P08037(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),B4GALT1,CC,1,1 of 22,0.99,4.55,0.06991,0.08913
GO:0003697,single-stranded DNA binding,Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01591|ens),IGJ,MF,1,1 of 22,0.99,4.55,0.06991,0.08913
GO:0031012,extracellular matrix,P30931(Evidence code:ISS/Database source:UniProtKB:P13726)P12763(Evidence code:IBA/Database source:PANTHER:PTN000352259), F3 AHSG,CC,2,2 of 137,1.98,1.46,0.07195,0.09156
GO:0006952,defense response,P19660(Evidence code:IEA/Database source:InterPro:IPR001894|I)P22226(Evidence code:IEA/Database source:InterPro:IPR001894|I)P54228(Evidence code:IEA/Database source:InterPro:IPR001894|I), CATHL2 CATHL1 CATHL6,BP,3,3 of 300,2.97,1,0.07252,0.09163
GO:0015629,actin cytoskeleton,P60712(Evidence code:ISS/Database source:UniProtKB:P60709),ACTB,CC,1,1 of 23,0.99,4.35,0.07283,0.09163
GO:0030674,"protein binding, bridging",Q3SYR8(Evidence code:IEA/Database source:UniProtKB:P01592|ens),IGJ,MF,1,1 of 23,0.99,4.35,0.07283,0.09163
GO:0030139,endocytic vesicle,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,CC,1,1 of 23,0.99,4.35,0.07283,0.09163
GO:0016903,"oxidoreductase activity, acting on the aldehyde or oxo group of donors",P80457(Evidence code:IBA/Database source:PANTHER:PTN000225632),XDH,MF,1,1 of 23,0.99,4.35,0.07283,0.09163
GO:0009612,response to mechanical stimulus,P30922(Evidence code:ISS/Database source:UniProtKB:P36222),CHI3L1,BP,1,1 of 23,0.99,4.35,0.07283,0.09163
GO:0008144,drug binding,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,MF,1,1 of 24,0.99,4.17,0.07575,0.0944
GO:0016525,negative regulation of angiogenesis,Q95121(Evidence code:IEA/Database source:InterPro:IPR033832),SERPINF1,BP,1,1 of 24,0.99,4.17,0.07575,0.0944
GO:0070555,response to interleukin-1,P30922(Evidence code:ISS/Database source:UniProtKB:P36222),CHI3L1,BP,1,1 of 24,0.99,4.17,0.07575,0.0944
GO:0003755,peptidyl-prolyl cis-trans isomerase activity,P62935(Evidence code:IEA/Database source:InterPro:IPR002130|I),PPIA,MF,1,1 of 24,0.99,4.17,0.07575,0.0944
GO:0006099,tricarboxylic acid cycle,Q9XSG3(Evidence code:IEA/Database source:UniProtKB-KW:KW-0816),IDH1,BP,1,1 of 24,0.99,4.17,0.07575,0.0944
GO:0005975,carbohydrate metabolic process,P30922(Evidence code:IEA/Database source:InterPro:IPR001223)P08037(Evidence code:IEA/Database source:InterPro:IPR003859), CHI3L1 B4GALT1,BP,2,2 of 144,1.98,1.39,0.07827,0.09737
GO:0031214,biomineral tissue development,P31096(Evidence code:IEA/Database source:UniProtKB-KW:KW-0091),SPP1,BP,1,1 of 25,0.99,4,0.07865,0.09747
GO:0046889,positive regulation of lipid biosynthetic process,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439006),APOE,BP,1,1 of 25,0.99,4,0.07865,0.09747
GO:0034612,response to tumor necrosis factor,P30922(Evidence code:ISS/Database source:UniProtKB:P36222),CHI3L1,BP,1,1 of 26,0.99,3.85,0.08155,0.1003
GO:0032680,regulation of tumor necrosis factor production,P24627(Evidence code:ISS/Database source:UniProtKB:P02788),LTF,BP,1,1 of 26,0.99,3.85,0.08155,0.1003
GO:0031072,heat shock protein binding,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,MF,1,1 of 26,0.99,3.85,0.08155,0.1003
GO:0030307,positive regulation of cell growth,P00735(Evidence code:IEA/Database source:UniProtKB:P19221|ens),F2,BP,1,1 of 26,0.99,3.85,0.08155,0.1003
GO:0051287,NAD binding,Q9XSG3(Evidence code:IEA/Database source:InterPro:IPR019818),IDH1,MF,1,1 of 27,0.99,3.7,0.08444,0.1035
GO:0005319,lipid transporter activity,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,MF,1,1 of 27,0.99,3.7,0.08444,0.1035
GO:0045069,regulation of viral genome replication,P62935(Evidence code:ISS/Database source:UniProtKB:P62937),PPIA,BP,1,1 of 28,0.99,3.57,0.08732,0.1064
GO:0042383,sarcolemma,O18738(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),DAG1,CC,1,1 of 28,0.99,3.57,0.08732,0.1064
GO:0004620,phospholipase activity,P11151(Evidence code:IDA/Database source:),LPL,MF,1,1 of 28,0.99,3.57,0.08732,0.1064
GO:0001649,osteoblast differentiation,P31096(Evidence code:IBA/Database source:PANTHER:PTN001635232),SPP1,BP,1,1 of 29,0.99,3.45,0.09019,0.1097
GO:0043524,negative regulation of neuron apoptotic process,Q03247(Evidence code:IBA/Database source:PANTHER:PTN000439007),APOE,BP,1,1 of 30,0.99,3.33,0.09305,0.1124
GO:0030193,regulation of blood coagulation,P41361(Evidence code:IEA/Database source:InterPro:IPR033829),SERPINC1,BP,1,1 of 30,0.99,3.33,0.09305,0.1124
GO:1900182,positive regulation of protein localization to nucleus,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 30,0.99,3.33,0.09305,0.1124
GO:0005507,copper ion binding,Q32P72(Evidence code:IEA/Database source:InterPro:IPR011707|I),CP,MF,1,1 of 30,0.99,3.33,0.09305,0.1124
GO:0004197,cysteine-type endopeptidase activity,P07688(Evidence code:IEA/Database source:InterPro:IPR012599),CTSB,MF,1,1 of 31,0.99,3.23,0.0959,0.1156
GO:0050660,flavin adenine dinucleotide binding,P80457(Evidence code:IEA/Database source:InterPro:IPR014307|I),XDH,MF,1,1 of 32,0.99,3.12,0.09874,0.1188
GO:0030170,pyridoxal phosphate binding,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,MF,1,1 of 35,0.99,2.86,0.1072,0.1281
GO:0097193,intrinsic apoptotic signaling pathway,P17697(Evidence code:ISS/Database source:UniProtKB:P10909-4),CLU,BP,1,1 of 35,0.99,2.86,0.1072,0.1281
GO:0009267,cellular response to starvation,P02769(Evidence code:ISS/Database source:UniProtKB:P02768),ALB,BP,1,1 of 35,0.99,2.86,0.1072,0.1281
GO:0090501,RNA phosphodiester bond hydrolysis,P15467(Evidence code:IEA/Database source:GO:0004540),RNASE4,BP,1,1 of 35,0.99,2.86,0.1072,0.1281
GO:0045944,positive regulation of transcription by RNA polymerase II,Q3T0Q4(Evidence code:ISS/Database source:UniProtKB:P22392)P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens), NME2 SERPINF2,BP,2,2 of 177,1.98,1.13,0.1101,0.1306
GO:0005777,peroxisome,P80457(Evidence code:IEA/Database source:UniProtKB-KW:KW-0576),XDH,CC,1,1 of 36,0.99,2.78,0.11,0.1306
GO:0006665,sphingolipid metabolic process,P26779(Evidence code:IEA/Database source:InterPro:IPR008373|I),PSAP,BP,1,1 of 36,0.99,2.78,0.11,0.1306
GO:0001701,in utero embryonic development,A6H7B5(Evidence code:IEA/Database source:UniProtKB:O88543|ens),COPS3,BP,1,1 of 36,0.99,2.78,0.11,0.1306
GO:0061077,chaperone-mediated protein folding,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,BP,1,1 of 38,0.99,2.63,0.1156,0.1364
GO:1902904,negative regulation of supramolecular fiber organization,P02662(Evidence code:IDA/Database source:),CSN1S1,BP,1,1 of 38,0.99,2.63,0.1156,0.1364
GO:0004540,ribonuclease activity,P15467(Evidence code:IBA/Database source:PANTHER:PTN001350296),RNASE4,MF,1,1 of 38,0.99,2.63,0.1156,0.1364
GO:0030198,extracellular matrix organization,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 39,0.99,2.56,0.1184,0.1394
GO:0051536,iron-sulfur cluster binding,P80457(Evidence code:IEA/Database source:InterPro:IPR001041|I),XDH,MF,1,1 of 40,0.99,2.5,0.1212,0.1424
GO:0031410,cytoplasmic vesicle,P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0968)P02702(Evidence code:IEA/Database source:UniProtKB-KW:KW-0968)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), CLU FOLR1 APOA1,CC,3,3 of 379,2.97,0.79,0.1217,0.1428
GO:0050769,positive regulation of neurogenesis,Q95121(Evidence code:IEA/Database source:InterPro:IPR033832),SERPINF1,BP,1,1 of 42,0.99,2.38,0.1267,0.1484
GO:0030027,lamellipodium,Q3T0Q4(Evidence code:ISS/Database source:UniProtKB:P22392),NME2,CC,1,1 of 44,0.99,2.27,0.1322,0.154
GO:0050900,leukocyte migration,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 44,0.99,2.27,0.1322,0.154
GO:0016485,protein processing,P30931(Evidence code:IEA/Database source:UniProtKB:P13726|ens),F3,BP,1,1 of 44,0.99,2.27,0.1322,0.154
GO:0052689,carboxylic ester hydrolase activity,P11151(Evidence code:IEA/Database source:InterPro:IPR000734|I),LPL,MF,1,1 of 45,0.99,2.22,0.1349,0.1563
GO:0008217,regulation of blood pressure,P02666(Evidence code:IEA/Database source:UniProtKB-KW:KW-0382),CSN2,BP,1,1 of 45,0.99,2.22,0.1349,0.1563
GO:0005882,intermediate filament,G3N0V2(Evidence code:IEA/Database source:InterPro:IPR001664),KRT1,CC,1,1 of 45,0.99,2.22,0.1349,0.1563
GO:0009055,electron transfer activity,P80457(Evidence code:IEA/Database source:InterPro:IPR001041|I),XDH,MF,1,1 of 46,0.99,2.17,0.1376,0.1592
GO:0005524,ATP binding,Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0067)P60712(Evidence code:IEA/Database source:UniProtKB-KW:KW-0067)Q0VCX2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0067), NME2 ACTB HSPA5,MF,3,3 of 403,2.97,0.74,0.1385,0.16
GO:0001934,positive regulation of protein phosphorylation,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens)Q2UVX4(Evidence code:ISS/Database source:UniProtKB:P01024), F2 C3,BP,2,2 of 205,1.98,0.98,0.1393,0.1606
GO:0019899,enzyme binding,P79345(Evidence code:IEA/Database source:UniProtKB:P61916|ens)Q7SIH1(Evidence code:IEA/Database source:UniProtKB:P01023|ens)P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens), NPC2 A2M APOA1,MF,3,3 of 405,2.97,0.74,0.14,0.1611
GO:0006816,calcium ion transport,P02666(Evidence code:IBA/Database source:PANTHER:PTN000161175),CSN2,BP,1,1 of 47,0.99,2.13,0.1403,0.1612
GO:0020037,heme binding,P80025(Evidence code:IEA/Database source:InterPro:IPR010255),LPO,MF,1,1 of 49,0.99,2.04,0.1457,0.1671
GO:0051015,actin filament binding,Q3SX14(Evidence code:IEA/Database source:InterPro:IPR007122),GSN,MF,1,1 of 50,0.99,2,0.1484,0.1699
GO:0045211,postsynaptic membrane,O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0628),DAG1,CC,1,1 of 51,0.99,1.96,0.1511,0.1721
GO:0043123,positive regulation of I-kappaB kinase/NF-kappaB signaling,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,BP,1,1 of 51,0.99,1.96,0.1511,0.1721
GO:0090305,nucleic acid phosphodiester bond hydrolysis,P15467(Evidence code:IEA/Database source:GO:0004519),RNASE4,BP,1,1 of 51,0.99,1.96,0.1511,0.1721
GO:0004519,endonuclease activity,P15467(Evidence code:IEA/Database source:UniProtKB-KW:KW-0255),RNASE4,MF,1,1 of 53,0.99,1.89,0.1564,0.1775
GO:0008234,cysteine-type peptidase activity,P07688(Evidence code:IEA/Database source:InterPro:IPR000668|I),CTSB,MF,1,1 of 53,0.99,1.89,0.1564,0.1775
GO:0060271,cilium assembly,Q3SX14(Evidence code:ISS/Database source:UniProtKB:P06396),GSN,BP,1,1 of 55,0.99,1.82,0.1617,0.1832
GO:0030141,secretory granule,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,CC,1,1 of 57,0.99,1.75,0.1669,0.1886
GO:0051480,regulation of cytosolic calcium ion concentration,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 57,0.99,1.75,0.1669,0.1886
GO:0000287,magnesium ion binding,Q9XSG3(Evidence code:IEA/Database source:InterPro:IPR019818),IDH1,MF,1,1 of 58,0.99,1.72,0.1696,0.1912
GO:0022900,electron transport chain,P80457(Evidence code:IEA/Database source:GO:0009055),XDH,BP,1,1 of 59,0.99,1.69,0.1722,0.1935
GO:0071902,positive regulation of protein serine/threonine kinase activity,P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens),LTF,BP,1,1 of 59,0.99,1.69,0.1722,0.1935
GO:0045202,synapse,O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0770),DAG1,CC,1,1 of 60,0.99,1.67,0.1748,0.1961
GO:0045861,negative regulation of proteolysis,P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens),F2,BP,1,1 of 62,0.99,1.61,0.1799,0.2008
GO:0002237,response to molecule of bacterial origin,P01888(Evidence code:IEA/Database source:UniProtKB:P01887|ens),B2M,BP,1,1 of 62,0.99,1.61,0.1799,0.2008
GO:0016616,"oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor",Q9XSG3(Evidence code:IEA/Database source:InterPro:IPR019818|I),IDH1,MF,1,1 of 62,0.99,1.61,0.1799,0.2008
GO:0030855,epithelial cell differentiation,P07688(Evidence code:IEA/Database source:UniProtKB:P07858|ens),CTSB,BP,1,1 of 63,0.99,1.59,0.1825,0.2034
GO:0006486,protein glycosylation,P08037(Evidence code:IEA/Database source:UniPathway:UPA00378),B4GALT1,BP,1,1 of 66,0.99,1.52,0.1902,0.2116
GO:0051346,negative regulation of hydrolase activity,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 67,0.99,1.49,0.1927,0.214
GO:0016757,"transferase activity, transferring glycosyl groups",P08037(Evidence code:IEA/Database source:InterPro:IPR003859),B4GALT1,MF,1,1 of 69,0.99,1.45,0.1978,0.2193
GO:0005667,transcription factor complex,F1MX50(Evidence code:IEA/Database source:UniProtKB:O88668|ens),CREG1,CC,1,1 of 70,0.99,1.43,0.2003,0.2217
GO:0007283,spermatogenesis,G3N2D8(Evidence code:IEA/Database source:UniProtKB:Q60928|ens),GGT1,BP,1,1 of 72,0.99,1.39,0.2053,0.2269
GO:0031965,nuclear membrane,O02853(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),PTGDS,CC,1,1 of 75,0.99,1.33,0.2128,0.2348
GO:0002682,regulation of immune system process,Q3SZR3(Evidence code:IEA/Database source:InterPro:IPR001500)G3N2D8(Evidence code:IEA/Database source:UniProtKB:Q60928|ens), ORM1 GGT1,BP,2,2 of 279,1.98,0.72,0.2219,0.2444
GO:0004518,nuclease activity,P15467(Evidence code:IEA/Database source:UniProtKB-KW:KW-0540),RNASE4,MF,1,1 of 79,0.99,1.27,0.2226,0.2448
GO:0019216,regulation of lipid metabolic process,P26779(Evidence code:IBA/Database source:PANTHER:PTN000159338),PSAP,BP,1,1 of 80,0.99,1.25,0.2251,0.2467
GO:0009615,response to virus,P79345(Evidence code:IEA/Database source:UniProtKB:P61916|ens),NPC2,BP,1,1 of 80,0.99,1.25,0.2251,0.2467
GO:0005179,hormone activity,O46375(Evidence code:IEA/Database source:UniProtKB-KW:KW-0372),TTR,MF,1,1 of 82,0.99,1.22,0.2299,0.2516
GO:0031625,ubiquitin protein ligase binding,P17697(Evidence code:ISS/Database source:UniProtKB:P10909),CLU,MF,1,1 of 83,0.99,1.2,0.2324,0.2538
GO:0016042,lipid catabolic process,P11151(Evidence code:IEA/Database source:UniProtKB-KW:KW-0442),LPL,BP,1,1 of 84,0.99,1.19,0.2348,0.2556
GO:0005125,cytokine activity,P31096(Evidence code:IEA/Database source:UniProtKB-KW:KW-0202),SPP1,MF,1,1 of 84,0.99,1.19,0.2348,0.2556
GO:0019221,cytokine-mediated signaling pathway,P30931(Evidence code:IBA/Database source:PANTHER:PTN000466212),F3,BP,1,1 of 86,0.99,1.16,0.2396,0.2604
GO:0001664,G-protein coupled receptor binding,P26779(Evidence code:IBA/Database source:PANTHER:PTN001352635),PSAP,MF,1,1 of 88,0.99,1.14,0.2443,0.2651
GO:0005622,intracellular,Q3T0Q4(Evidence code:IBA/Database source:PANTHER:PTN000887110),NME2,CC,1,1 of 95,0.99,1.05,0.2608,0.2825
GO:0005654,nucleoplasm,A6H7B5(Evidence code:IEA/Database source:UniProtKB:Q9UNS2|ens)O18738(Evidence code:IEA/Database source:UniProtKB-SubCell:SL), COPS3 DAG1,CC,2,2 of 315,1.98,0.63,0.2634,0.2848
GO:0042995,cell projection,P08037(Evidence code:IEA/Database source:UniProtKB-KW:KW-0966)Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0966), B4GALT1 NME2,CC,2,2 of 317,1.98,0.63,0.2657,0.2869
GO:0008134,transcription factor binding,F1MX50(Evidence code:IEA/Database source:UniProtKB:O88668|ens),CREG1,MF,1,1 of 98,0.99,1.02,0.2677,0.2886
GO:0030335,positive regulation of cell migration,Q0VCX2(Evidence code:ISS/Database source:UniProtKB:P11021),HSPA5,BP,1,1 of 100,0.99,1,0.2723,0.2931
GO:0043231,intracellular membrane-bounded organelle,Q2KIF2(Evidence code:IEA/Database source:UniProtKB:P02750|ens)P07688(Evidence code:IEA/Database source:UniProtKB:A0A024R374)P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0492), LRG1 CTSB CLU,CC,3,3 of 1927,2.97,0.16,0.288,0.3091
GO:0051345,positive regulation of hydrolase activity,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 107,0.99,0.93,0.2881,0.3091
GO:0007166,cell surface receptor signaling pathway,P26201(Evidence code:IEA/Database source:InterPro:IPR033076)P00735(Evidence code:IEA/Database source:UniProtKB:P00734|ens), CD36 F2,BP,2,2 of 344,1.98,0.58,0.2968,0.3176
GO:0005759,mitochondrial matrix,P10790(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),FABP3,CC,1,1 of 111,0.99,0.9,0.297,0.3176
GO:0008285,negative regulation of cell proliferation,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 119,0.99,0.84,0.3145,0.3357
GO:0033993,response to lipid,P26201(Evidence code:ISS/Database source:UniProtKB:Q08857),CD36,BP,1,1 of 122,0.99,0.82,0.3209,0.342
GO:0005739,mitochondrion,P10790(Evidence code:IEA/Database source:UniProtKB-KW:KW-0496)P17697(Evidence code:IEA/Database source:UniProtKB-KW:KW-0496), FABP3 CLU,CC,2,2 of 380,1.98,0.53,0.3378,0.3595
GO:0001817,regulation of cytokine production,P24627(Evidence code:IEA/Database source:InterPro:IPR030684),LTF,BP,1,1 of 131,0.99,0.76,0.3398,0.361
GO:0048037,cofactor binding,F1MX50(Evidence code:IEA/Database source:InterPro:IPR012349),CREG1,MF,1,1 of 132,0.99,0.76,0.3419,0.3627
GO:0004857,enzyme inhibitor activity,P02666(Evidence code:IEA/Database source:UniProtKB-KW:KW-0481),CSN2,MF,1,1 of 139,0.99,0.72,0.3562,0.3772
GO:0019904,protein domain specific binding,P06868(Evidence code:IPI/Database source:UniProtKB:P08169),PLG,MF,1,1 of 145,0.99,0.69,0.3682,0.3893
GO:0009117,nucleotide metabolic process,Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0546),NME2,BP,1,1 of 147,0.99,0.68,0.3721,0.3929
GO:0003676,nucleic acid binding,P15467(Evidence code:IEA/Database source:InterPro:IPR001427),RNASE4,MF,1,1 of 989,0.99,0.1,0.3767,0.397
GO:0006915,apoptotic process,P30922(Evidence code:IEA/Database source:UniProtKB-KW:KW-0053),CHI3L1,BP,1,1 of 151,0.99,0.66,0.38,0.3999
GO:0051603,proteolysis involved in cellular protein catabolic process,P07688(Evidence code:IEA/Database source:UniProtKB:P07858|ens),CTSB,BP,1,1 of 157,0.99,0.64,0.3915,0.4114
GO:0016310,phosphorylation,Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0418),NME2,BP,1,1 of 164,0.99,0.61,0.4047,0.4233
GO:0008284,positive regulation of cell proliferation,P00735(Evidence code:IEA/Database source:UniProtKB:P19221|ens),F2,BP,1,1 of 164,0.99,0.61,0.4047,0.4233
GO:0030030,cell projection organization,Q3SX14(Evidence code:IEA/Database source:UniProtKB-KW:KW-0970),GSN,BP,1,1 of 164,0.99,0.61,0.4047,0.4233
GO:0005768,endosome,P02702(Evidence code:IEA/Database source:UniProtKB-KW:KW-0967),FOLR1,CC,1,1 of 165,0.99,0.61,0.4066,0.4245
GO:0045597,positive regulation of cell differentiation,P28800(Evidence code:IEA/Database source:UniProtKB:P08697|ens),SERPINF2,BP,1,1 of 167,0.99,0.6,0.4103,0.4277
GO:0007186,G-protein coupled receptor signaling pathway,P15497(Evidence code:IEA/Database source:UniProtKB:P02647|ens),APOA1,BP,1,1 of 168,0.99,0.6,0.4122,0.429
GO:0016301,kinase activity,Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0418),NME2,MF,1,1 of 174,0.99,0.57,0.4231,0.4397
GO:0051270,regulation of cellular component movement,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 180,0.99,0.56,0.4339,0.4502
GO:0000166,nucleotide binding,P60712(Evidence code:IEA/Database source:UniProtKB-KW:KW-0547)Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0547)Q0VCX2(Evidence code:IEA/Database source:UniProtKB-KW:KW-0547), ACTB NME2 HSPA5,MF,3,3 of 677,2.97,0.44,0.4758,0.4929
GO:0008270,zinc ion binding,Q8SPP7(Evidence code:IEA/Database source:InterPro:IPR006619),PGLYRP1,MF,1,1 of 207,0.99,0.48,0.4798,0.4963
GO:0032991,protein-containing complex,P60712(Evidence code:ISS/Database source:UniProtKB:P60709)P02769(Evidence code:ISS/Database source:UniProtKB:P02768)P24627(Evidence code:IEA/Database source:UniProtKB:P02788|ens), ACTB ALB LTF,CC,3,3 of 1693,2.97,0.18,0.4939,0.5101
GO:0043085,positive regulation of catalytic activity,P26779(Evidence code:IEA/Database source:GO:0008047),PSAP,BP,1,1 of 229,0.99,0.44,0.5144,0.5304
GO:0005730,nucleolus,P07688(Evidence code:IEA/Database source:UniProtKB:A0A024R374),CTSB,CC,1,1 of 232,0.99,0.43,0.5189,0.5343
GO:0010468,regulation of gene expression,P00735(Evidence code:IEA/Database source:UniProtKB:P19221|ens),F2,BP,1,1 of 870,0.99,0.11,0.5278,0.541
GO:0071310,cellular response to organic substance,Q2KIS7(Evidence code:IEA/Database source:UniProtKB:P05452|ens),CLEC3B,BP,1,1 of 238,0.99,0.42,0.5279,0.541
GO:0008092,cytoskeletal protein binding,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,MF,1,1 of 238,0.99,0.42,0.5279,0.541
GO:0006811,ion transport,P24627(Evidence code:IEA/Database source:UniProtKB-KW:KW-0406),LTF,BP,1,1 of 278,0.99,0.36,0.5834,0.5969
GO:0010629,negative regulation of gene expression,P02662(Evidence code:IMP/Database source:),CSN1S1,BP,1,1 of 281,0.99,0.36,0.5873,0.6
GO:0031966,mitochondrial membrane,P17697(Evidence code:IEA/Database source:UniProtKB-SubCell:SL),CLU,CC,1,1 of 289,0.99,0.35,0.5975,0.6094
GO:0005198,structural molecule activity,G3N0V2(Evidence code:IEA/Database source:InterPro:IPR001664),KRT1,MF,1,1 of 294,0.99,0.34,0.6037,0.6148
GO:0001932,regulation of protein phosphorylation,P15497(Evidence code:IEA/Database source:UniProtKB:Q00623|ens),APOA1,BP,1,1 of 304,0.99,0.33,0.6159,0.6263
GO:0042127,regulation of cell proliferation,P08037(Evidence code:IEA/Database source:UniProtKB:P15535|ens),B4GALT1,BP,1,1 of 309,0.99,0.32,0.6219,0.6314
GO:0030054,cell junction,O18738(Evidence code:IEA/Database source:UniProtKB-KW:KW-0965),DAG1,CC,1,1 of 315,0.99,0.32,0.6289,0.6375
GO:0003677,DNA binding,Q0P569(Evidence code:IEA/Database source:UniProtKB-KW:KW-0238)P02769(Evidence code:ISS/Database source:UniProtKB:P02768), NUCB1 ALB,MF,2,2 of 481,1.98,0.42,0.6652,0.6734
GO:0006355,"regulation of transcription, DNA-templated",F1MX50(Evidence code:IEA/Database source:UniProtKB:O88668|ens),CREG1,BP,1,1 of 662,0.99,0.15,0.7264,0.7341
GO:0031982,vesicle,P12763(Evidence code:IDA/Database source:)G3N2D8(Evidence code:IEA/Database source:UniProtKB:Q60928|ens), AHSG GGT1,CC,2,2 of 1000,1.98,0.2,0.7726,0.7796
GO:0036094,small molecule binding,O02853(Evidence code:IEA/Database source:InterPro:IPR002345)P02754(Evidence code:IEA/Database source:InterPro:IPR002345), PTGDS LGB,MF,2,2 of 800,1.98,0.25,1,1
GO:0016740,transferase activity,P08037(Evidence code:IEA/Database source:UniProtKB-KW:KW-0808)Q3T0Q4(Evidence code:IEA/Database source:UniProtKB-KW:KW-0808), B4GALT1 NME2,MF,2,2 of 633,1.98,0.32,1,1
GO:0051246,regulation of protein metabolic process,Q3SZV7(Evidence code:IEA/Database source:UniProtKB:Q91X72|ens),HPX,BP,1,1 of 576,0.99,0.17,1,1
GO:0050790,regulation of catalytic activity,P07688(Evidence code:IEA/Database source:InterPro:IPR012599),CTSB,BP,1,1 of 388,0.99,0.26,1,1
GO:0015031,protein transport,Q32KV6(Evidence code:IEA/Database source:UniProtKB-KW:KW-0653),SIL1,BP,1,1 of 394,0.99,0.25,1,1
GO:0042981,regulation of apoptotic process,Q3T0Q4(Evidence code:IBA/Database source:PANTHER:PTN000142983),NME2,BP,1,1 of 317,0.99,0.32,1,1
